<SEC-DOCUMENT>0001193125-25-169818.txt : 20250731
<SEC-HEADER>0001193125-25-169818.hdr.sgml : 20250731
<ACCEPTANCE-DATETIME>20250731060555
ACCESSION NUMBER:		0001193125-25-169818
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250729
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250731
DATE AS OF CHANGE:		20250731

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Larimar Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001374690
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				203857670
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36510
		FILM NUMBER:		251169144

	BUSINESS ADDRESS:	
		STREET 1:		THREE BALA PLAZA EAST. SUITE 506
		CITY:			BALA CYNWYD
		STATE:			PA
		ZIP:			19004
		BUSINESS PHONE:		844-511-9056

	MAIL ADDRESS:	
		STREET 1:		THREE BALA PLAZA EAST. SUITE 506
		CITY:			BALA CYNWYD
		STATE:			PA
		ZIP:			19004

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZAFGEN, INC.
		DATE OF NAME CHANGE:	20100301

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZAFGEN INC
		DATE OF NAME CHANGE:	20060906
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d35960d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lrmr="http://www.larimartx.com/20250729" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2025-07-29_to_2025-07-29" id="ixv-301">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2025-07-29_to_2025-07-29">0001374690</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="lrmr-20250729.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2025-07-29_to_2025-07-29"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-07-29</xbrli:startDate> <xbrli:endDate>2025-07-29</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2025-07-29_to_2025-07-29" id="ixv-312">8-K</ix:nonNumeric></span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of The Securities Exchange Act of 1934</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2025-07-29_to_2025-07-29" format="ixt:datemonthdayyearen" id="ixv-313">July&#160;29, 2025</ix:nonNumeric></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2025-07-29_to_2025-07-29" id="ixv-314">Larimar Therapeutics, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2025-07-29_to_2025-07-29" format="ixt-sec:stateprovnameen" id="ixv-315">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2025-07-29_to_2025-07-29" id="ixv-316">001-36510</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2025-07-29_to_2025-07-29" id="ixv-317">20-3857670</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(I.R.S. Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2025-07-29_to_2025-07-29" id="ixv-318">Three Bala Plaza East</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2025-07-29_to_2025-07-29" id="ixv-319">Suite 506</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2025-07-29_to_2025-07-29" id="ixv-320">Bala Cynwyd</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2025-07-29_to_2025-07-29" format="ixt-sec:stateprovnameen" id="ixv-321">Pennsylvania</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2025-07-29_to_2025-07-29" id="ixv-322">19004</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2025-07-29_to_2025-07-29" id="ixv-323">(844)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2025-07-29_to_2025-07-29" id="ixv-324">511-9056</ix:nonNumeric></span></p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report.)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2025-07-29_to_2025-07-29" format="ixt-sec:boolballotbox" id="ixv-325">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2025-07-29_to_2025-07-29" format="ixt-sec:boolballotbox" id="ixv-326">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2025-07-29_to_2025-07-29" format="ixt-sec:boolballotbox" id="ixv-327">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2025-07-29_to_2025-07-29" format="ixt-sec:boolballotbox" id="ixv-328">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-07-29_to_2025-07-29" id="ixv-329">Common Stock, par value $0.001 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-07-29_to_2025-07-29" id="ixv-330">LRMR</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-07-29_to_2025-07-29" format="ixt-sec:exchnameen" id="ixv-331">Nasdaq Global Market</ix:nonNumeric></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2025-07-29_to_2025-07-29" format="ixt-sec:boolballotbox" id="ixv-332">&#9744;</ix:nonNumeric></p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;1.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;29, 2025, Larimar Therapeutics, Inc. (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Company</span></span>&#8221;) entered into an underwriting agreement (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Underwriting Agreement</span></span>&#8221;) with Leerink Partners LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named therein (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Underwriters</span></span>&#8221;), relating to the issuance and sale of an aggregate of 18,750,000 shares (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Firm Shares</span></span>&#8221;) of common stock, par value $0.001 per share (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Common Stock</span></span>&#8221;), of the Company at a public offering price of $3.20 per share (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Offering</span></span>&#8221;). Pursuant to the terms of the Underwriting Agreement, the Company granted the Underwriters an option, exercisable for 30 days following the date of the Underwriting Agreement, to purchase up to an additional 2,812,500 shares of Common Stock (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Optional Shares</span></span>&#8221; and together with the Firm Shares, the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Shares</span></span>&#8221;) at the same price, less the underwriting discounts and commissions, which the Underwriters exercised in full on July&#160;30, 2025. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Giving effect to the sale of the Optional Shares, the net proceeds to the Company from the Offering, after deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $64.4&#160;million.&#160;All of the Shares in the Offering are being sold by the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC, Guggenheim Securities, LLC, Truist Securities<span style="font-weight:bold"></span>, Inc. and&#160;William Blair &amp; Company, L.L.C. acted as joint bookrunning managers for the Offering. The Offering is expected to close on July&#160;31, 2025, subject to the satisfaction of customary closing conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Offering is being made pursuant to a prospectus supplement, dated July&#160;29, 2025 (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Prospectus Supplement</span></span>&#8221;), filed with the Securities and Exchange Commission (&#8220;<span style="font-weight:bold"><span style="font-style:italic">Commission</span></span>&#8221;) on July&#160;30, 2025 and an accompanying base prospectus that forms a part of the Company&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-3</span> (File <span style="white-space:nowrap">No.&#160;333-279275),</span> filed with the Commission on May&#160;9, 2024 and declared effective by the Commission on May&#160;24, 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement and may be subject to limitations agreed upon by the contracting parties. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing summary of the Underwriting Agreement is qualified in its entirety by reference to the Underwriting Agreement that is filed as Exhibit&#160;1.1 to this Current Report on <span style="white-space:nowrap">Form&#160;8-K</span> and is incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of the legal opinion of Goodwin Procter LLP relating to the legality of the issuance and sale of the Shares in the Offering is filed as Exhibit 5.1 to this Current Report on Form <span style="white-space:nowrap">8-K.</span> </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Below is a list of exhibits included with this Current Report on Form <span style="white-space:nowrap">8-K.</span> </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit<br/>No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Document</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8194;1.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d35960dex11.htm">Underwriting Agreement, dated July&#160;29, 2025, by and among the Company and Leerink Partners LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named therein* </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8194;5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d35960dex51.htm">Opinion of Goodwin Procter LLP* </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d35960dex51.htm">Consent of Goodwin Procter LLP (included in Exhibit&#160;5.1)* </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top;text-align:left">*</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Filed herewith </p></td></tr></table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border-spacing:0;margin-left:auto">


<tr>

<td style="width:12%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:87%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3">Larimar Therapeutics, Inc.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Carole S. Ben-Maimon, M.D.</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-style:italic">Name:</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">Carole S. Ben-Maimon, M.D.</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-style:italic">Title:</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic">President and Chief Executive Officer</span></td></tr>
</table></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: July 31, 2025 </p>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d35960dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>18,750,000 Shares of Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Larimar Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>UNDERWRITING AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">July&nbsp;29, 2025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LEERINK PARTNERS LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GUGGENHEIM SECURITIES, LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representatives of the several
Underwriters </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o LEERINK PARTNERS LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">53 State Street,
40th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts 02109 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o GUGGENHEIM
SECURITIES, LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">330 Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10017
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Introductory.
</B>Larimar Therapeutics, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in <U>Schedule A</U> (the
&#147;<B>Underwriters</B>&#148;) an aggregate of 18,750,000 shares of its common stock, par value $0.001 per share (the &#147;<B>Shares</B>&#148;). The 18,750,000 Shares to be sold by the Company are called the &#147;<B>Firm Shares</B>.&#148; In
addition, the Company has granted to the Underwriters an option to purchase up to an additional 2,812,500 Shares as provided in Section&nbsp;2. The additional 2,812,500 Shares to be sold by the Company pursuant to such option are collectively called
the &#147;<B>Optional Shares</B>.&#148; The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are called the &#147;<B>Offered Shares</B>.&#148; Leerink Partners LLC (&#147;<B>Leerink Partners</B>&#148;) and
Guggenheim Securities, LLC (&#147;<B>Guggenheim Securities</B>&#148;) have agreed to act as representatives of the several Underwriters (in such capacity, the &#147;<B>Representatives</B>&#148;) in connection with the offering and sale of the
Offered Shares. To the extent there are no additional underwriters listed on <U>Schedule A</U>, the term &#147;Representatives&#148; as used herein shall mean you, as Underwriters, and the term &#147;Underwriters&#148; shall mean either the singular
or the plural, as the context requires. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has prepared and filed with the Securities and Exchange Commission (the
&#147;<B>Commission</B>&#148;) a shelf registration statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> File <FONT STYLE="white-space:nowrap">No.&nbsp;333-279275,</FONT> including a base prospectus (the &#147;<B>Base Prospectus</B>&#148;)
to be used in connection with the public offering and sale of the Offered Shares. Such registration statement, as amended, including the financial statements, exhibits and schedules thereto, in the form in which it became effective under the
Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder (collectively, the &#147;<B>Securities Act</B>&#148;), including all documents incorporated or deemed to be incorporated by reference therein and any
information deemed to be a part thereof at the time of effectiveness pursuant to Rule 430B under the Securities Act, is called the &#147;<B>Registration Statement</B>.&#148; Any registration statement filed by the Company pursuant to Rule 462(b)
under the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Securities Act in connection with the offer and sale of the Offered Shares is called the &#147;<B>Rule 462(b) Registration Statement</B>,&#148; and from and after the date and time of filing of
any such Rule&nbsp;462(b) Registration Statement the term &#147;Registration Statement&#148; shall include the Rule&nbsp;462(b) Registration Statement. The preliminary prospectus supplement, dated July&nbsp;29, 2025, describing the Offered Shares
and the offering thereof (the &#147;<B>Preliminary Prospectus Supplement</B>&#148;), together with the Base Prospectus, is called the &#147;<B>Preliminary Prospectus</B>,&#148; and the Preliminary Prospectus and any other prospectus supplement to
the Base Prospectus in preliminary form that describes the Offered Shares and the offering thereof and is used prior to the filing of the Prospectus (as defined below), together with the Base Prospectus, is called a &#147;<B>preliminary
prospectus</B>.&#148; As used herein, the term &#147;<B>Prospectus</B>&#148; shall mean the final prospectus supplement to the Base Prospectus that describes the Offered Shares and the offering thereof (the &#147;<B>Final Prospectus
Supplement</B>&#148;), together with the Base Prospectus, in the form first used by the Underwriters to confirm sales of the Offered Shares<B></B>&nbsp;or in the form first made available to the Underwriters by the Company to meet requests of
purchasers pursuant to Rule&nbsp;173 under the Securities Act. References herein to the Preliminary Prospectus, any preliminary prospectus and the Prospectus shall refer to both the prospectus supplement and the Base Prospectus components of such
prospectus. As used herein, &#147;<B>Applicable Time</B>&#148; is 7:00 p.m., New York City time, on July&nbsp;29, 2025. As used herein, &#147;<B>free writing prospectus</B>&#148; has the meaning set forth in Rule 405 under the Securities Act, and
&#147;<B>Time of Sale Prospectus</B>&#148; means the Preliminary Prospectus, as amended or supplemented immediately prior to the Applicable Time, together with the information included on <U>Schedule <FONT STYLE="white-space:nowrap">B-1</FONT></U>
hereto and free writing prospectuses, if any, identified in <U>Schedule <FONT STYLE="white-space:nowrap">B-2</FONT></U> hereto. As used herein, <B>&#147;Road Show&#148;</B> means a &#147;road show&#148; (as defined in Rule 433 under the Securities
Act) relating to the offering of the Offered Shares contemplated hereby that is a &#147;written communication&#148; (as defined in Rule 405 under the Securities Act). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All references in this Agreement to the Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus
and the Prospectus shall include the documents incorporated or deemed to be incorporated by reference therein. All references in this Agreement to financial statements and schedules and other information which are &#147;contained,&#148;
&#147;included&#148; or &#147;stated&#148; in, or &#147;part of&#148; the Registration Statement, the Rule 462(b) Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus, the Time of Sale Prospectus or the
Prospectus, and all other references of like import, shall be deemed to mean and include all such financial statements and schedules and other information which is or is deemed to be incorporated by reference in the Registration Statement, the
Rule&nbsp;462(b) Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus, the Time of Sale Prospectus or the Prospectus, as the case may be. All references in this Agreement to amendments or supplements to
the Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus, the Time of Sale Prospectus or the Prospectus shall be deemed to mean and include the filing of any document under the Securities Exchange Act
of 1934, as amended, and the rules and regulations promulgated thereunder (collectively, the &#147;<B>Exchange Act</B>&#148;) that is or is deemed to be incorporated by reference in the Registration Statement, the Preliminary Prospectus, any
preliminary prospectus, the Base Prospectus, or the Prospectus, as the case may be. All references in this Agreement to (i)&nbsp;the Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus or the
Prospectus, any amendments or supplements to any of the foregoing, or any free writing prospectus, shall include any copy thereof filed with the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval System
(&#147;<B>EDGAR</B>&#148;) and (ii)&nbsp;the Prospectus shall be deemed to include any &#147;electronic Prospectus&#148; provided for use in connection with the offering of the Offered Shares as contemplated by Section&nbsp;3(n) of this Agreement.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that the Company has only one subsidiary, then all references herein to
&#147;subsidiaries&#148; of the Company shall be deemed to refer to such single subsidiary, <U>mutatis</U> <U>mutandis</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
hereby confirms its agreements with the Underwriters as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1.</B> <B>Representations and Warranties of the
Company</B>. The Company hereby represents, warrants and covenants to each Underwriter, as of the date of this Agreement, as of the First Closing Date (as hereinafter defined) and as of each Option Closing Date (as hereinafter defined), if any, as
follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><I>Effectiveness of Registration Statement</I></B><I>.</I> The Registration Statement has been declared effective
by the Commission under the Securities Act. The Company has complied, to the Commission&#146;s satisfaction, with all requests of the Commission for additional or supplemental information, if any. No stop order suspending the effectiveness of either
Registration Statement is in effect and no proceedings for such purpose have been instituted or are pending or, to the Company&#146;s knowledge, are contemplated or threatened by the Commission. At the time the Registration Statement was originally
filed with the Commission, the Company met the then-applicable requirements for use of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act. The documents incorporated or deemed to be incorporated by reference in the
Registration Statement, the Time of Sale Prospectus and the Prospectus, at the time they were or hereafter are filed with the Commission, or became effective under the Exchange Act, as the case may be, complied and will comply in all material
respects with the requirements of the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><I>Compliance with Registration Requirements</I></B><I>.</I> Each of
the Registration Statement, any Rule 462(b) Registration Statement and any post-effective amendment thereto, as of the applicable Effective Date, complied and, until such time as the Underwriters are no longer required to deliver a Prospectus in
order to confirm sales of the Shares, will comply in all material respects with the Securities Act and the rules and regulations of the Commission thereunder (the &#147;<B>Rules and Regulations</B>&#148;). The Preliminary Prospectus and the
Prospectus, at the time each was filed with the Commission, complied in all material respects with the requirements of the Securities Act and the Rules and Regulations. Each Preliminary Prospectus delivered to the Underwriters for use in connection
with this Offering and the Prospectus was or will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation <FONT STYLE="white-space:nowrap">S-T.</FONT>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B><I>Registration Statement Disclosure</I></B><I>. </I>The Registration Statement, when it became effective, did not and, as
amended or supplemented, if applicable, will not (i)&nbsp;contain, as of the date of such amendment or supplement, an untrue statement of a material fact, or (ii)&nbsp;omit to state a material fact required to be stated therein or necessary to make
the statements therein not misleading; <I>provided</I>, <I>however</I>, that this representation and warranty shall not apply to any information contained in or omitted from the Registration Statement or any amendment thereto
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in reliance upon and in conformity with information furnished in writing to the Company by or on behalf of any Underwriter through the Representative specifically for use therein. The parties
hereto agree that such information provided by or on behalf of any Underwriter through the Representative consists solely of the material referred to in Section&nbsp;9(b) hereof. Each &#147;forward-looking statement&#148; (within the meaning of
Section&nbsp;27A of the Securities Act or Section&nbsp;21E of the Exchange Act) contained or incorporated by reference in the Registration Statement, the Preliminary Prospectus or the Prospectus has been made or reaffirmed with a reasonable basis
and has been disclosed in good faith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B><I>Prospectus Disclosure</I></B><I>.</I> The Time of Sale Prospectus, as of the
Applicable Time, did not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The Prospectus
will not, as of its date, as of the First Closing Date or as of any Option Closing Date, contain an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading. Each free writing prospectus (i)&nbsp;complies in all material respects with the applicable provisions of the Securities Act and the Rules and Regulations, (ii)&nbsp;does not conflict with
the information contained in the Registration Statement, the Time of Sale Prospectus or the Prospectus and (iii)&nbsp;does not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements
therein, in the light of the circumstances in which they were made, not misleading. No representation and warranty is made in this Section&nbsp;1(d) with respect to any information contained in or omitted from the Time of Sale Prospectus or the
Prospectus in reliance upon and in conformity with information furnished in writing to the Company by or on behalf of any Underwriter through the Representative specifically for use therein. The parties hereto agree that such information provided by
or on behalf of any Underwriter through the Representative consists solely of the material referred to in Section&nbsp;9(b) hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B><I>Ineligible Issuer</I></B><I>.</I> At the earliest time (i)&nbsp;after the filing of the Registration Statement that the
Company or another offering participant made a bona fide offer (within the meaning of Rule 164(h)(2) of the Securities Act) of the Shares and (ii)&nbsp;at the date hereof, the Company was not and is not an &#147;ineligible issuer,&#148; as defined
in Rule 405 of the Securities Act, including (but not limited to) the Company or any subsidiary in the preceding three years not having been convicted of a felony or misdemeanor or having been made the subject of a judicial or administrative decree
or order as described in Rule 405 of the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B><I>Free Writing Prospectuses</I></B><I>. </I>Each free writing
prospectus conformed or will conform in all material respects to the requirements of the Securities Act and the Rules and Regulations on the date of first use, and the Company has complied with the requirements of Rule 433 under the Securities Act
with respect to each free writing prospectus including, without limitation, all prospectus delivery, filing, record retention and legending requirements applicable to any such free writing prospectus. The Company has not (i)&nbsp;distributed any
offering material in connection with the Offering other than any Preliminary Prospectus, the Prospectus, and any free writing prospectus set forth on <U>Schedule <FONT STYLE="white-space:nowrap">B-2</FONT></U> hereto, or (ii)&nbsp;filed, referred
to, approved, used or authorized the use of any &#147;free writing prospectus&#148; as defined in Rule 405 under the Securities Act with respect to the Offering or the Shares, except for any free writing prospectus set forth in <U>Schedule <FONT
STYLE="white-space:nowrap">B-2</FONT></U> hereto and any electronic Road Show previously approved by the Representative. The Company has retained in accordance with the Securities Act and the Rules and Regulations all free writing prospectuses that
were not required to be filed pursuant to the Securities Act and the Rules and Regulations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> <B><I>Independent Accountants</I></B><I>. </I>PricewaterhouseCoopers LLP, which
has expressed its opinion with respect to the financial statements (which term as used in this Agreement includes the related notes thereto) filed with the Commission as a part of the Registration Statement, the Time of Sale Prospectus or the
Prospectus, is an independent registered public accounting firm as required by the Securities Act, the Exchange Act, and the rules of the Public Company Accounting Oversight Board (&#147;<B>PCAOB</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <B><I>No Material Adverse Effect</I></B><I>. </I>Since<B><I></I></B>&nbsp;the date of the latest audited financial statements
included in the Registration Statement, the Time of Sale Prospectus and the Prospectus, and, except as disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus, (A)&nbsp;neither the Company nor any of its subsidiaries
listed in <U>Exhibit A</U> hereto (&#147;<B>Subsidiaries</B>&#148;) has (i)&nbsp;sustained any loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or
court or governmental action, order or decree, (ii)&nbsp;issued or granted any securities (other than pursuant to employee benefit plans, qualified stock option plans or other equity compensation plans or arrangements existing on the date hereof and
disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus), (iii) incurred any material liability or obligation, direct or contingent, other than liabilities and obligations that were incurred in the ordinary course of
business, (iv)&nbsp;entered into any material transaction not in the ordinary course of business, or (v)&nbsp;declared or paid any dividend on its share capital; and (B)&nbsp;there has not been any change in the share capital, long-term debt, net
current assets or short-term debt of the Company or any of its Subsidiaries or any adverse change, or any development involving a prospective adverse change, in or affecting the condition (financial or otherwise), results of operations,
shareholders&#146; equity, properties, management, business or prospects of the Company and its Subsidiaries taken as a whole. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>
<B><I>Capitalization and Other Capital Stock Matters</I></B><I>. </I>The Company has an authorized capitalization as set forth in the Registration Statement, Time of Sale Prospectus and the Prospectus, and all of the issued shares of the Company
have been duly authorized and validly issued, are fully paid and <FONT STYLE="white-space:nowrap">non-assessable,</FONT> conform in all material respects to the description thereof contained in the Registration Statement, the Time of Sale Prospectus
and the Prospectus and were not issued in violation of any preemptive right, resale right, right of first refusal or similar right. All of the Company&#146;s options, warrants and other rights to purchase or exchange any securities for shares of the
Company&#146;s capital stock have been duly authorized and validly issued, and conform in all material respects to the description thereof contained in the Registration Statement, the Time of Sale Prospectus and the Prospectus. All of the issued
shares of capital stock or other ownership interest of each subsidiary of the Company have been duly authorized and validly issued, are fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and are owned directly or indirectly by the
Company, free and clear of all liens, encumbrances, equities or claims, except for such liens, encumbrances, equities or claims as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.
&#147;<B>Material Adverse Effect</B>&#148; shall mean any material adverse change or effect on or affecting (i)&nbsp;the business, earnings, assets, liabilities, prospects, condition (financial or otherwise), operations, general affairs, management,
financial position, stockholders&#146; equity or results of operations of the Company and the Subsidiaries taken as a whole, or (ii)&nbsp;the ability of the Company to perform its obligations under this Agreement, including this issuance and sale of
the Shares, or to consummate the transactions contemplated by this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> <B><I>Authorization of the Offered Shares</I></B><I>. </I>The Shares to be
delivered on the First Closing Date and any Option Closing Date, if any, have been duly authorized and, when issued and delivered in accordance with this Agreement, will be validly issued, fully paid and
<FONT STYLE="white-space:nowrap">non-assessable,</FONT> will conform in all material respects to the description thereof contained in the Registration Statement, the Time of Sale Prospectus and the Prospectus, will be issued in compliance with
federal and state securities laws and will be free of statutory and contractual preemptive rights, rights of first refusal and similar rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> <B><I>Incorporation and Good Standing of the Company and Subsidiaries</I></B><I>. </I>The Company and each of its Subsidiaries have
been duly organized, validly existing as a corporation and in good standing under the laws of their respective jurisdictions of organization. The Company and each of its Subsidiaries are, and will be, duly licensed or qualified as a foreign
corporation for transaction of business and in good standing under the laws of each other jurisdiction in which their respective ownership or lease of property or the conduct of their respective businesses requires such license or qualification, and
have all corporate power and authority necessary to own or hold their respective properties and to conduct their respective businesses as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus, except where the
failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> <B><I><FONT STYLE="white-space:nowrap">Non-Contravention</FONT> of Existing Instruments</I></B><I>. </I>The issue and sale of the
Shares, the execution, delivery and performance of this Agreement by the Company, the consummation of the transactions contemplated hereby and the application of the proceeds from the sale of the Shares as described under &#147;Use of Proceeds&#148;
in the Registration Statement, the Time of Sale Prospectus and the Prospectus will not (i)&nbsp;conflict with or result in a breach or violation of any of the terms or provisions of, impose any lien, charge or encumbrance upon any property or assets
of the Company and its Subsidiaries, or constitute a default under, any indenture, mortgage, deed of trust, loan agreement, license, lease or other agreement or instrument to which the Company or any of its Subsidiaries is a party or by which the
Company or any of its Subsidiaries is bound or to which any of the property or assets of the Company or any of its Subsidiaries is subject; (ii)&nbsp;result in any violation of the provisions of the certificate of incorporation or bylaws (or similar
organizational documents) of the Company or any of its Subsidiaries; or (iii)&nbsp;result in any violation of any statute or any judgment, order, decree, rule or regulation of any court or governmental agency or body having jurisdiction over the
Company or any of its Subsidiaries or any of their properties or assets, except, with respect to clauses (i)&nbsp;and (iii), for such conflicts, breaches, violations, liens, charges, encumbrances or defaults that would not, individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> <B><I>Government Consents</I></B><I>. </I>No consent, approval, authorization or
order of, or filing, registration or qualification with, any court or governmental agency or body having jurisdiction over the Company or any of its Subsidiaries or any of their properties or assets is required for the issue and sale of the Shares,
the execution, delivery and performance of this Agreement by the Company, the consummation of the transactions contemplated hereby, the application of the proceeds from the sale of the Shares as described under &#147;Use of Proceeds&#148; in the
Registration Statement, the Time of Sale Prospectus and the Prospectus, except for (i)&nbsp;the registration of the Shares under the Securities Act; (ii)&nbsp;such consents, approvals, authorizations, orders, filings, registrations or qualifications
as may be required under the Exchange Act, and applicable state or foreign securities laws and/or the bylaws and rules of the Financial Industry Regulatory Authority (the &#147;<B>FINRA</B>&#148;) in connection with the sale of the Shares by the
Underwriters; and (iii)&nbsp;the inclusion of the Shares on The Nasdaq Global Market (&#147;<B>Nasdaq</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n)</B>
<B><I>Corporate Power</I></B><I>. </I>The Company has all requisite corporate power and authority to execute, deliver and perform its obligations under this Agreement. This Agreement has been duly and validly authorized, executed and delivered by
the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o)</B> <B><I>Corporate Documents</I></B><I>. </I>Neither the Company nor any of its Subsidiaries (i)&nbsp;is in
violation of its certificate of incorporation or bylaws (or similar organizational documents), (ii) is in default, and no event has occurred that, with notice or lapse of time or both, would constitute such a default, in the due performance or
observance of any term, covenant, condition or other obligation contained in any indenture, mortgage, deed of trust, loan agreement, license or other agreement or instrument to which it is a party or by which it is bound or to which any of its
properties or assets is subject, or (iii)&nbsp;is in violation of any statute or any order, rule or regulation of any court or governmental agency or body having jurisdiction over it or its property or assets or has failed to obtain any license,
permit, certificate, franchise or other governmental authorization or permit necessary to the ownership of its property or to the conduct of its business, except in the case of clauses (ii)&nbsp;and (iii), to the extent any such conflict, breach,
violation or default would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(p)</B>
<B><I>No Material Actions or Proceedings</I></B><I>. </I>There are no legal or governmental proceedings pending to which the Company or any of its Subsidiaries is a party or of which any property or assets of the Company or any of its Subsidiaries
is the subject that, if determined adversely to the Company, would, in the aggregate, reasonably be expected to have a Material Adverse Effect; and to the Company&#146;s knowledge, no such proceedings are threatened in writing by governmental
authorities or others. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(q)</B> <B><I>Financial Statements</I></B><I>. </I>The historical financial statements (including the related
notes and supporting schedules) included or incorporated by reference, in the Registration Statement, the Time of Sale Prospectus, and the Prospectus comply as to form in all material respects with the requirements of Regulation <FONT
STYLE="white-space:nowrap">S-X</FONT> under the Securities Act (&#147;<B>Regulation <FONT STYLE="white-space:nowrap">S-X</FONT></B>&#148;) and present fairly in all material respects the financial condition, results of operations and cash flows of
the entities purported to be shown thereby at the dates and for the periods indicated and have been prepared in conformity with generally accepted accounting principles in the United States (&#147;<B>GAAP</B>&#148;) applied on a consistent basis
throughout the periods involved (except (i)&nbsp;as may be otherwise indicated in such financial statements or the notes thereto, or (ii)&nbsp;in the case of unaudited interim statements, to the extent they may exclude footnotes and are subject to
normal and recurring <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments that are not reasonably expected to be material in amount). All disclosures contained in the Registration Statement, the Time of Sale Prospectus and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Prospectus regarding <FONT STYLE="white-space:nowrap">&#147;non-GAAP</FONT> financial measures&#148; (as such term is defined by the rules and regulations of the Commission) comply with
Regulation G of the Exchange Act and Item 10 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> of the Securities Act, to the extent applicable. There are no financial statements (historical or pro forma) that are required to be included in
the Registration Statement, the Time of Sale Prospectus or the Prospectus that are not so included as required. The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement, the
Time of Sale Prospectus and the Prospectus fairly present the information called for in all material respects and have been prepared in accordance with the Commission&#146;s rules and guidelines applicable thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(r)</B> <B><I>Material Contracts</I></B><I>. </I>There are no contracts or other documents required to be described in the Registration
Statement, the Time of Sale Prospectus or the Prospectus or to be filed as exhibits to the Registration Statement that are not described and filed as required. The statements made in the Registration Statement, the Time of Sale Prospectus and
Prospectus, insofar as they purport to constitute summaries of the terms of the contracts and other documents described and filed, constitute accurate summaries of the terms of such contracts and documents in all material respects. Neither the
Company nor any of its Subsidiaries has knowledge that any other party to any such contract or other document has any intention not to render full performance as contemplated by the terms thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(s)</B> <B><I>Internal Controls Over Financial Reporting</I></B><I>. </I>The Company and each of its Subsidiaries maintain a system of
&#147;internal controls over financial reporting&#148; (as defined in <FONT STYLE="white-space:nowrap">Rule&nbsp;13a-15(f)</FONT> of the Exchange Act) designed to provide reasonable assurances regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with GAAP, including, but not limited to, internal accounting controls sufficient to provide reasonable assurance that (i)&nbsp;transactions are executed in accordance with
management&#146;s general or specific authorization, (ii)&nbsp;transactions are recorded as necessary to permit preparation of the Company&#146;s financial statements in conformity with GAAP and to maintain accountability for its assets,
(iii)&nbsp;access to the Company&#146;s assets is permitted only in accordance with management&#146;s general or specific authorization, (iv)&nbsp;the recorded accountability for the Company&#146;s assets is compared with existing assets at
reasonable intervals and appropriate action is taken with respect to any differences, and (v)&nbsp;the interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement, the Time of Sale
Prospectus and the Prospectus fairly present the information called for in all material respects and are prepared in accordance with the Commission&#146;s rules and guidelines applicable thereto. As of the date of the most recent balance sheet of
the Company and its consolidated Subsidiaries audited by PricewaterhouseCoopers LLP, there were no &#147;material weaknesses&#148; (as defined by the PCAOB) in the Company&#146;s internal controls over financial reporting, or any fraud, whether or
not material, that involves management or other employees of the Company and its Subsidiaries who have a significant role in the Company&#146;s internal controls; and since the end of the latest audited fiscal year, there has been no change in the
Company&#146;s internal control over financial reporting (whether or not remediated) that has materially affected, or is reasonably likely to materially affect, the Company&#146;s internal control over financial reporting. The Company&#146;s board
of directors has, subject to the exceptions, cure periods and the phase in periods specified in the Exchange rules (&#147;<B>Exchange Rules</B>&#148;), validly appointed an audit committee to oversee internal accounting controls whose composition
satisfies the applicable requirements of the Exchange Rules and the Company&#146;s board of directors and/or the audit committee has adopted a charter that satisfies the requirements of the Exchange Rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(t)</B> <B><I>Disclosure Controls and Procedures</I></B><I>. </I>The Company and its
Subsidiaries maintain &#147;disclosure controls and procedures&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> of the Exchange Act) that comply with the requirements of the Exchange Act and that have been designed to
ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission&#146;s rules and forms,
including controls and procedures designed to ensure that such information is accumulated and communicated to the Company&#146;s management as appropriate to allow timely decisions regarding required disclosure. The Company and its Subsidiaries have
carried out evaluations of the effectiveness of their disclosure controls and procedures as required by Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(u)</B> <B><I>Critical Accounting Policies</I></B><I>. </I>The section entitled &#147;Critical Accounting Policies and Significant
Judgments and Estimates&#148; incorporated by reference in the Registration Statement, the Time of Sale Prospectus and the Prospectus accurately describes in all material respects (i)&nbsp;the accounting policies that the Company believes are the
most important in the portrayal of the Company&#146;s financial condition and results of operations and that require management&#146;s most difficult, subjective or complex judgments (&#147;<B>Critical Accounting Policies</B>&#148;); (ii) the
judgments and uncertainties affecting the application of Critical Accounting Policies; and (iii)&nbsp;the likelihood that materially different amounts would be reported under different conditions or using different assumptions, and an explanation
thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> <B><I>Compliance with Sarbanes Oxley Act</I></B>. There is and has been no failure on the part of the Company or, to
the knowledge of the Company, any of the Company&#146;s directors or officers, in their capacities as such, to comply with any provision of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated in connection therewith (the
&#147;<B>Sarbanes Oxley Act</B>&#148;) that are applicable to the Company or its directors or officers in their capacities as directors or officers of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(w)</B> <B><I>Registration</I></B><I>. </I>The shares of Common Stock are registered pursuant to Section&nbsp;12(b) of the Exchange Act and
listed on Nasdaq; the Company has taken no action designed to, or reasonably likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act or delisting the Common Stock from Nasdaq, nor has the Company
received any notification that the Commission or Nasdaq is contemplating terminating such registration or listing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(x)</B>
<B><I>Related-Party Transactions</I></B><I>. </I>No relationship, direct or indirect, exists between or among the Company, on the one hand, and the directors, officers, shareholders, customers or suppliers of the Company, on the other hand, that is
required to be described in the Registration Statement, the Time of Sale Prospectus or the Prospectus which is not so described. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(y)</B> <B><I>No Price Stabilization or Manipulation; Compliance with Regulation M</I></B><I>. </I>The Company has not taken and will not
take, directly or indirectly, any action designed to, or which might reasonably be expected to cause or result in, or which constitutes: (i)&nbsp;the stabilization or manipulation of the price of the Common Stock or any other security of the Company
to facilitate the sale or resale of the Shares or (ii)&nbsp;a violation of Regulation M. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(z)</B> <B><I>No Integration</I></B><I>. </I>The Company has not sold or issued any
securities that would be integrated with the offering and sale of the Shares contemplated by this Agreement pursuant to the Securities Act or the interpretations thereof by the Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(aa)</B> <B><I>FINRA Matters</I></B><I>. </I>All of the information provided to the Underwriters or to counsel for the Underwriters by the
Company and, to the Company&#146;s knowledge, its officers, directors and the holders of any securities (debt or equity) or options to acquire any securities of the Company in connection with the offering of the Shares is true, complete and correct
in all material respects and compliant with FINRA rules and, to the Company&#146;s knowledge, any letters, filings or other supplemental information provided to FINRA pursuant to FINRA Rules or NASD Conduct Rules is true, complete and correct in all
material respects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(bb)</B> <B><I>Accuracy of Description of Capital Stock, Risk Factors and Underwriting Disclosure</I></B><I>.
</I>The statements set forth in the Time of Sale Prospectus and the Prospectus under the caption &#147;Description of Capital Stock&#148;, insofar as it purports to constitute a summary of the terms of the Common Stock, and under the captions
&#147;Risk Factors&#148; and &#147;Underwriting&#148;, insofar as they purport to describe the provisions of the laws and documents referred to therein, are accurate and complete in all material respects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(cc)</B> <B><I>Company Not an &#147;Investment Company.&#148;</I></B> The Company is not and, at all times up to and including consummation
of the transactions contemplated by this Agreement, and after giving effect to application of the net proceeds of the Offering as described in the Time of Sale Prospectus and the Prospectus, will not be, required to register as an &#147;investment
company&#148; under the Investment Company Act of 1940, as amended, and is not and will not be an entity &#147;controlled&#148; by an &#147;investment company&#148; within the meaning of such act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(dd)</B> <B><I>Brokers</I></B><I>. </I>Neither the Company nor any of its Subsidiaries is a party to any contract, agreement or
understanding with any person (other than this Agreement) that would give rise to a valid claim against any of them or any Underwriter for a brokerage commission, finder&#146;s fee or like payment in connection with the offering and sale of the
Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ee)</B> <B><I>Title to Property</I></B><I>. </I>The Company and each of its Subsidiaries have good and marketable title in
fee simple to all real property and good and marketable title to all personal property owned by them, that are material to the business of the Company, in each case free and clear of all liens, encumbrances and defects, except such liens,
encumbrances and defects as do not materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company and its Subsidiaries. All assets held under lease by the
Company and its Subsidiaries, that are material to the business of the Company, are held by them under valid, subsisting and enforceable leases, with such exceptions as do not materially interfere with the use made and proposed to be made of such
assets by the Company and its Subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ff)</B> <B><I>Intellectual Property Rights</I></B><I>. </I>The Company and each of its
Subsidiaries owns, possesses, or can acquire on reasonable terms, all Intellectual Property necessary for the conduct of the Company&#146;s and its Subsidiaries&#146; business as now conducted or as proposed to be conducted, as described in the
Registration Statement, the Time of Sale Prospectus and the Prospectus. Furthermore, (A)&nbsp;to the knowledge of the Company, there is no infringement, misappropriation or violation by third parties of any such Intellectual Property; (B)&nbsp;there
is no pending or, to the knowledge of the Company, threatened, action, suit, proceeding or claim by others challenging the Company&#146;s or any of its Subsidiaries&#146; rights in or to any such Intellectual Property, and the Company is unaware of
any facts which would form a reasonable basis for any such claim; (C)&nbsp;the Intellectual Property owned by the Company and its Subsidiaries, and to the knowledge of the Company, the Intellectual Property licensed to the Company and its
Subsidiaries, in each case that is necessary for the conduct of the Company&#146;s and its Subsidiaries&#146; business as now conducted or as proposed to be conducted, has not been adjudged invalid or unenforceable, in whole or in part, and there is
no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by others challenging the validity or scope of any such Intellectual Property and the Company is unaware of any facts which would form a reasonable basis
for any such claim; (D)&nbsp;there is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by others that the Company or any of its Subsidiaries infringes, misappropriates or otherwise violates any
Intellectual Property or other proprietary rights of others, and neither the Company or any of its Subsidiaries has received any written notice of such claim and the Company is unaware of any other fact which would form a reasonable basis for any
such claim; (E)&nbsp;to the Company&#146;s knowledge, no employee of the Company or any of its Subsidiaries is in or has ever been in material violation of any employment contract, patent disclosure agreement, invention assignment agreement, <FONT
STYLE="white-space:nowrap">non-competition</FONT> agreement, <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement, nondisclosure agreement or any restrictive covenant to or with a former employer where the basis of such violation
relates to such employee&#146;s employment with the Company nor any of its Subsidiaries or actions undertaken by the employee while employed with the Company or any of its Subsidiaries; (F)&nbsp;with respect to the Intellectual Property that is
necessary for the conduct of the Company&#146;s and its Subsidiaries&#146; business as now conducted or as proposed to be conducted, there is no prior art or public or commercial activity of which the Company is aware that may render any patent
included with respect to such Intellectual Property invalid or that would preclude the issuance of any patent on any patent application included in such Intellectual Property, which has not been disclosed to the U.S. Patent and Trademark Office or
the relevant foreign patent authority, as the case may be; (G)&nbsp;to the Company&#146;s knowledge, the issued patents included in the Intellectual Property that is necessary for the conduct of the Company&#146;s and its Subsidiaries&#146; business
as now conducted or as proposed to be conducted are valid and enforceable and the Company is unaware of any facts that would preclude the issuance of a valid and enforceable patent on any pending patent application included in such Intellectual
Property; (H)&nbsp;with respect to the Intellectual Property that is necessary for the conduct of the Company&#146;s and its Subsidiaries&#146; business as now conducted or proposed to be conducted and that is owned or purported to be owned by the
Company, the Company has taken reasonable steps necessary to secure the interests of the Company in such Intellectual Property from all employees, consultants, agents or contractors that developed (in whole or in part) such Intellectual Property;
(I)&nbsp;no government funding, facilities or resources of a university, college, other educational institution or research center was used in the development of any Intellectual Property necessary for the conduct of the Company&#146;s and it
subsidiaries&#146; business as now conducted or proposed to be conducted and that is owned or purported to be owned by the Company that would confer upon any governmental agency or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
body, university, college, other educational institution or research center any claim or right in or to any such Intellectual Property; and (J)&nbsp;to the Company&#146;s knowledge, none of the
technology employed by the Company has been obtained or is being used by the Company in violation of the rights of any entity. &#147;Intellectual Property&#148; shall mean all patents, patent applications, trade and service marks, trade and service
mark registrations, trade names, copyrights, licenses, inventions, trade secrets, domain names, technology, <FONT STYLE="white-space:nowrap">know-how</FONT> and other intellectual property in the United States and foreign jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(gg)</B> <B><I>All Necessary Permits, etc</I></B><I>. </I>The Company has submitted and possesses, or qualifies for applicable exemptions
to, such valid and current registrations, listings, approvals, clearances, licenses, certificates, authorizations or permits and supplements or amendments thereto issued or required by the appropriate state, federal or foreign regulatory agencies or
bodies necessary to conduct their business (&#147;<B>Permits</B>&#148;), including, without limitation, all such Permits required by the U.S. Food and Drug Administration (the &#147;<B>FDA</B>&#148;), the U.S. Department of Health and Human Services
(&#147;<B>HHS</B>&#148;), the U.S. Centers for Medicare&nbsp;&amp; Medicaid Services (&#147;<B>CMS</B>&#148;), the European Medicines Agency (&#147;<B>EMA</B>&#148;), Health Canada or any other comparable state, federal or foreign agencies or bodies
to which it is subject, and the Company has not received any notice of proceedings relating to the revocation or modification of, or <FONT STYLE="white-space:nowrap">non-compliance</FONT> with, any such Permit, except for such Permits, the lack of
which would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(hh)</B>
<B><I>Compliance with Health Care Laws</I></B><I>. </I>The Company and, to the Company&#146;s knowledge, its directors, employees and agents (while acting in such capacity) are and at all times have been in material compliance with, all health care
laws applicable to the Company, or any of its products or activities, including, but not limited to, the federal Anti-Kickback Statute (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7b(b)),</FONT> the Anti-Inducement Law (42 U.S.C. <FONT
STYLE="white-space:nowrap">Section&nbsp;1320a-7a(a)(5)),</FONT> the civil False Claims Act (31 U.S.C. Section&nbsp;3729 et seq.), the administrative False Claims Law (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7b(a)),</FONT> the
Stark law (42 U.S.C. Section&nbsp;1395nn), the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. Section&nbsp;1320d et seq.) as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C.
Section&nbsp;17921 et seq.), the exclusion laws (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7),</FONT> the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section&nbsp;301 et seq.), the Controlled Substances Act (21 U.S.C.
Section&nbsp;801 et seq.), the Public Health Service Act (42 U.S.C. Section&nbsp;201 et seq.), the Clinical Laboratory Improvement Amendments of 1988 (42 U.S.C. Section&nbsp;263a), Medicare (Title XVIII of the Social Security Act), Medicaid (Title
XIX of the Social Security Act), and the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, the regulations promulgated pursuant to such laws, and any other state, federal or
foreign law, accreditation standards, regulation, memorandum, opinion letter, or other issuance which imposes legally binding requirements on manufacturing, development, testing, labeling, advertising, marketing, promotion, distribution, reporting,
kickbacks, patient or program charges, recordkeeping, claims process, documentation requirements, medical necessity, referrals, the hiring of employees or acquisition of services or supplies from those who have been excluded from government health
care programs, quality, safety, privacy, security, licensure, accreditation or any other aspect of providing health care, clinical laboratory or diagnostics products or services (collectively, &#147;<B>Health Care Laws</B>&#148;). The Company has
not received any notification, correspondence or any other written or oral communication, including notification of any pending or threatened claim, suit, proceeding, hearing, enforcement, investigation, arbitration or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other action from any governmental authority, including, without limitation, the FDA, the EMA, Health Canada, the U.S. Federal Trade Commission, the U.S. Drug Enforcement Administration, CMS,
HHS&#146;s Office of Inspector General, the U.S. Department of Justice and state Attorneys General or similar agencies of potential or actual <FONT STYLE="white-space:nowrap">non-compliance</FONT> by, or liability of, the Company under any Health
Care Laws, except, with respect to any of the foregoing, such as would not, individually or in the aggregate, result in a Material Adverse Effect. To the Company&#146;s knowledge, there are no facts or circumstances that would reasonably be expected
to give rise to material liability of the Company under any Health Care Laws. Neither the Company, nor any of its Subsidiaries, is a party to or has any ongoing reporting obligations pursuant to any corporate integrity agreements, monitoring
agreements, deferred prosecution agreements, consent decrees, settlement orders, plan of correction or similar agreements with or imposed by any governmental authority for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with any Health Care
Law. The statements with respect to Health Care Laws and the Company&#146;s compliance therewith included in the Registration Statement, the Time of Sale Prospectus and the Prospectus fairly summarize the matters therein described. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B><I>Clinical Data and Regulatory Compliance</I></B><I>. </I>The studies, tests and preclinical and clinical trials conducted by
or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Prospectus or the Prospectus, or the results of which are referred to in the Registration
Statement, the Time of Sale Prospectus or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols submitted to the FDA or comparable regulatory agencies outside of the U.S., as
applicable, and all applicable statutes, rules and regulations of the FDA, the EMA, Health Canada and other comparable regulatory agencies outside of the U.S. to which they are subject, including, without limitation, 21 C.F.R. Parts 50, 54, 56, 58,
312, and 812; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Prospectus or the Prospectus do not contain any misstatement of a material fact or omit a material fact
necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Registration Statement, the Time of Sale Prospectus or the Prospectus the results of which reasonably call into
question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Prospectus or Prospectus; and except as described in the Registration Statement, the Time of Sale Prospectus or
the Prospectus, the Company has not received any notices or other correspondence from the FDA, EMA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable
authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and,
to the Company&#146;s knowledge, there are no reasonable grounds for the same. There has not been any material violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory
authority that could reasonably be expected to require investigation, corrective action or enforcement action. None of the Company or its Subsidiaries nor any of their respective employees or agents, officers or directors have been excluded,
suspended or debarred from participation in any U.S. state or federal health care program or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry, claim, investigation, or any other proceeding that could
reasonably be expected to result in debarment, suspension, or exclusion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(jj)</B> <B><I>Cybersecurity and Data Protection</I></B><I>. </I>The Company and its
Subsidiaries&#146; information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, &#147;<B>IT Systems</B>&#148;) are adequate for, and operate and perform in all
material respects as required in connection with the operation of the business of the Company and its Subsidiaries as currently conducted, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other
corruptants. The Company and its Subsidiaries have implemented and maintained commercially reasonable physical, technical and administrative controls, policies, procedures, and safeguards to maintain and protect their material confidential
information and the integrity, continuous operation, redundancy and security of all IT Systems and data, including &#147;Personal Data,&#148; used in connection with their businesses (collectively, &#147;<B>Sensitive Data</B>&#148;).
&#147;<B>Personal Data</B>&#148; means (i)&nbsp;a natural person&#146;s name, street address, telephone number, <FONT STYLE="white-space:nowrap">e-mail</FONT> address, photograph, social security number or tax identification number, driver&#146;s
license number, passport number, credit card number, bank information, or customer or account number; (ii)&nbsp;any information which would qualify as &#147;personally identifying information&#148; under the Federal Trade Commission Act, as amended;
(iii) &#147;personal data&#148; as defined by GDPR (as defined below); (iv) any information which would qualify as &#147;protected health information&#148; under the Health Insurance Portability and Accountability Act of 1996, as amended by the
Health Information Technology for Economic and Clinical Health Act (collectively, &#147;<B>HIPAA</B>&#148;); and (v)&nbsp;any other piece of information that allows the identification of such natural person, or his or her family, or permits the
collection or analysis of any data related to an identified person&#146;s health or sexual orientation. There have been no breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been remedied without
material cost or liability or the duty to notify any other person, nor any incidents under internal review or investigations relating to the same. The Company and its Subsidiaries are presently in material compliance with all applicable laws or
statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to
the protection of such IT Systems and Sensitive Data from unauthorized use, access, misappropriation or modification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(kk)</B>
<B><I>Compliance with Data Privacy and Security Laws</I></B><I>. </I>The Company and its Subsidiaries are, and at all prior times were, in material compliance with all applicable state and federal data privacy and security laws and regulations,
including without limitation HIPAA, the European Union General Data Protection Regulation (&#147;<B>GDPR</B>&#148;) (EU 2016/679), and other similar state privacy laws (collectively, the &#147;<B>Privacy Laws</B>&#148;). To ensure compliance with
the Privacy Laws, the Company and its Subsidiaries have in place, comply with, and take appropriate steps reasonably designed to ensure compliance in all material respects with their policies and procedures relating to data privacy and security and
the collection, storage, use, disclosure, handling, and analysis of Personal Data (the &#147;<B>Policies</B>&#148;). The Company and its Subsidiaries have at all times made all disclosures to users or customers required by applicable laws and
regulatory rules or requirements, and none of such disclosures made or contained in any Policy have, to the knowledge of the Company, been inaccurate or in violation of any applicable laws and regulatory rules or requirements in any material
respect. The Company further certifies that neither it nor any of its Subsidiaries: (i)&nbsp;has received notice of any actual or potential liability under or relating to, or actual or potential violation of, any of the Privacy Laws, and has no
knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii)&nbsp;is currently conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action pursuant to any
Privacy Law; or (iii)&nbsp;is a party to any order, decree, or agreement that imposes any obligation or liability under any Privacy Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ll)</B> <B><I>No Government Prohibitions</I></B><I>. </I>The Company has not had any
product, clinical laboratory or manufacturing site that manufactured products used by the Company (whether Company-owned or, to the Company&#146;s knowledge, that of a third party manufacturer for the Company&#146;s products) subject to a
governmental authority (including FDA) shutdown or import or export prohibition, nor received any FDA Form 483 or other governmental authority notice of inspectional observations, &#147;warning letters,&#148; &#147;untitled letters,&#148; requests
to make changes to the Company&#146;s products, processes or operations, or similar correspondence or notice from the FDA or other governmental authority alleging or asserting material noncompliance with any applicable Health Care Laws. To the
Company&#146;s knowledge, neither the FDA nor any other governmental authority is considering such action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(mm)</B> <B><I>No Recalls
or Safety Notices</I></B><I>. </I>Except as disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus, (A)&nbsp;there have been no recalls, field notifications, field corrections, market withdrawals or replacements,
warnings, &#147;dear doctor&#148; letters, investigator notices, safety alerts or other notice of action relating to an alleged lack of safety, efficacy, or regulatory compliance of the Company&#146;s products (&#147;<B>Safety Notices</B>&#148;) and
(B)&nbsp;to the Company&#146;s knowledge, there are no facts that would be reasonably likely to result in (x)&nbsp;a Safety Notice with respect to the Company&#146;s products or services, (y)&nbsp;a change in labeling of any of the Company&#146;s
respective products or services, or (z)&nbsp;a termination or suspension of marketing or testing of any of the Company&#146;s products or services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(nn)</B> <B><I>Insurance</I></B><I>. </I>The Company and each of its Subsidiaries maintain insurance from insurers of recognized financial
responsibility in such amounts and covering such risks is commercially reasonable in accordance with customary practices for companies engaged in similar businesses and similar industries for the conduct of their respective businesses and the value
of their respective properties and as is customary for companies engaged in similar businesses in similar industries. All policies of insurance of the Company and its subsidiaries are in full force and effect; the Company and each of its
Subsidiaries are in compliance with the terms of such policies in all material respects; neither the Company nor any of its Subsidiaries has received notice from any insurer or agent of such insurer that capital improvements or other expenditures
are required or necessary to be made in order to continue such insurance; there are no material claims by the Company or any of its Subsidiaries under any such policy or instrument as to which any insurance company is denying liability or defending
under a reservation of rights clause; and neither the Company nor any such Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from
similar insurers as may be necessary to continue its business at a cost that would not reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(oo)</B> <B><I>Tax Law Compliance</I></B><I>. </I>The Company and each of its Subsidiaries have filed all federal, state, local and foreign
tax returns required to be filed through the date hereof, subject to permitted extensions, and have paid all taxes due except where the failure to file or pay would not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect, and no tax deficiency has been determined adversely to the Company or any of its Subsidiaries, nor does the Company have any knowledge of any tax deficiencies that have been, or would reasonably be expected to be asserted against the
Company, that would, in the aggregate, reasonably be expected to have a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(pp)</B> <B><I>No Labor Disputes</I></B><I>. </I>No labor disturbance or dispute with the
employees of the Company or any of its Subsidiaries exists or, to the knowledge of the Company, is imminent that could reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(qq)</B> <B><I>ERISA Compliance</I></B><I>. </I>(i)&nbsp;Each &#147;employee benefit plan&#148; (within the meaning of Section&nbsp;3(3) of
the Employee Retirement Security Act of 1974, as amended (&#147;<B>ERISA</B>&#148;)) for which the Company or any member of its &#147;Controlled Group&#148; (defined as any organization which is a member of a controlled group of corporations within
the meaning of Section&nbsp;414 of the Internal Revenue Code of 1986, as amended (the &#147;<B>Code</B>&#148;)) would have any liability (each a &#147;<B>Plan</B>&#148;) has been maintained in compliance in all material respects with its terms and
with the requirements of all applicable statutes, rules and regulations including ERISA and the Code; (ii)&nbsp;no prohibited transaction, within the meaning of Section&nbsp;406 of ERISA or Section&nbsp;4975 of the Code, has occurred with respect to
any Plan excluding transactions effected pursuant to a statutory or administrative exemption; (iii)&nbsp;with respect to each Plan subject to Title IV of ERISA (A)&nbsp;no &#147;reportable event&#148; (within the meaning of Section&nbsp;4043(c) of
ERISA) has occurred or is reasonably expected to occur that would result in a material loss to the Company, (B)&nbsp;no &#147;accumulated funding deficiency&#148; (within the meaning of Section&nbsp;302 of ERISA or Section&nbsp;412 of the Code),
whether or not waived, has occurred or is reasonably expected to occur, (C)&nbsp;the fair market value of the assets under each Plan that is required to be funded exceeds the present value of all benefits accrued under such Plan (determined based on
those assumptions used to fund such Plan), and (D)&nbsp;neither the Company or any member of its Controlled Group has incurred, or reasonably expects to incur, any liability under Title IV of ERISA (other than contributions to the Plan or premiums
to the Pension Benefit Guaranty Corporation in the ordinary course and without default) in respect of a Plan (including a &#147;multiemployer plan&#148;, within the meaning of Section&nbsp;4001(c)(3) of ERISA); and (iv)&nbsp;each Plan that is
intended to be qualified under Section&nbsp;401(a) of the Code is so qualified and nothing has occurred, to the Company&#146;s knowledge, whether by action or by failure to act, which would cause the loss of such qualification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(rr)</B> <B><I>Compliance with Environmental Laws</I></B><I>. </I>The Company and each of its Subsidiaries (i)&nbsp;are, and at all times
prior hereto were, in compliance with all laws, regulations, ordinances, rules, orders, judgments, decrees, permits or other legal requirements of any governmental authority, including without limitation any international, foreign, national, state,
provincial, regional, or local authority, relating to pollution, the protection of human health or safety, the environment, or natural resources, or to use, handling, storage, manufacturing, transportation, treatment, discharge, disposal or release
of hazardous or toxic substances or wastes, pollutants or contaminants (&#147;<B>Environmental Laws</B>&#148;) applicable to such entity, which compliance includes, without limitation, obtaining, maintaining and complying with all permits and
authorizations and approvals required by Environmental Laws to conduct their respective businesses, and (ii)&nbsp;have not received written notice or otherwise have knowledge of any actual or alleged violation of Environmental Laws, or of any actual
or potential liability for or other obligation concerning the presence, disposal or release of hazardous or toxic substances or wastes, pollutants or contaminants, except in the case of clauses (i)&nbsp;and (ii), to the extent any
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such <FONT STYLE="white-space:nowrap">non-compliance,</FONT> violation, liability or other obligation would not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect. Except as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus, (x)&nbsp;there are no proceedings that are pending, or to the Company&#146;s knowledge, threatened, against the Company or any of its
Subsidiaries under Environmental Laws in which a governmental authority is also a party, other than such proceedings regarding which it is reasonably believed no monetary sanctions of $100,000 or more will be imposed, (y)&nbsp;the Company and its
Subsidiaries are not aware of any issues regarding compliance with Environmental Laws, including any pending or proposed Environmental Laws, or liabilities or other obligations under Environmental Laws or concerning hazardous or toxic substances or
wastes, pollutants or contaminants, that would reasonably be expected to have a Material Adverse Effect, and (z)&nbsp;neither the Company nor its Subsidiaries anticipate material capital expenditures relating to Environmental Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ss)</B> <B><I>Anti-Corruption and Anti-Bribery Laws</I></B><I>. </I>Neither the Company nor any Subsidiary nor, to the Company&#146;s
knowledge, any director, officer, agent, employee, affiliate or other person acting on behalf of the Company or any Subsidiary, has authorized the giving of, offer or promise to give or (i)&nbsp;made any unlawful contribution, gift, entertainment or
other unlawful expense relating to political activity; (ii)&nbsp;made any direct or indirect unlawful payment to any domestic governmental official, &#147;foreign official&#148; (as defined in the U.S. Foreign Corrupt Practices Act of 1977, as
amended, and the rules and regulations thereunder (collectively, the &#147;<B>FCPA</B>&#148;)) or employee; (iii)&nbsp;violated or is in violation of any provision of the FCPA, UK Bribery Act, any applicable
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> anti-bribery statute or regulation or any locally applicable corruption laws; (iv)&nbsp;made any bribe, rebate, payoff, influence payment, kickback or other unlawful payment; or (v)&nbsp;received
notice of any investigation, proceeding or inquiry by any governmental agency, authority or body regarding any of the matters in clauses (i)-(iv) above; and the Company and the Subsidiaries and, to the Company&#146;s knowledge, the Company&#146;s
affiliates have conducted their respective businesses in compliance with the FCPA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(tt)</B> <B><I>Money Laundering Laws</I></B><I>. </I>The operations of the Company and the Subsidiaries are and have been conducted at
all times in compliance with applicable financial record-keeping and reporting requirements, including those of the Bank Secrecy Act, as amended by Title III of the Uniting and Strengthening America by Providing Appropriate Tools Required to
Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT Act) (Title III of Pub. L. <FONT STYLE="white-space:nowrap">107-56</FONT> (signed into law 18 October&nbsp;26, 2001)) (the &#147;<B>USA Patriot Act</B>&#148;), and those of the Currency and
Foreign Transactions Reporting Act of 1970, as amended, and the money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines issued, administered or
enforced by any governmental agency (collectively, the &#147;<B>Money Laundering Laws</B>&#148;) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or the
Subsidiaries with respect to the Money Laundering Laws is pending or, to the Company&#146;s knowledge, threatened. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(uu)</B> <B><I>Sanctions</I></B><I>. </I>None of the Company nor any Subsidiary nor, to
the knowledge of the Company, any officer, director, agent, employee, affiliate or any person acting on behalf of the Company or any Subsidiary is or, since the more recent of (i)&nbsp;April&nbsp;24, 2019 and (ii)&nbsp;ten (10) years since the date
of this Agreement, has been (A)&nbsp;engaged in any services (including financial services), transfers of goods, software, or technology, or any other business activity related to (i)&nbsp;Belarus, Cuba, North Korea, Iran, Russia, Syria, and certain
regions of Ukraine (Crimea, Donetsk, Kherson and Luhansk and Zaporizhzhia) (&#147;<B>Sanctioned Countries</B>&#148;), (ii) the government of any Sanctioned Country, (iii)&nbsp;any person, entity or organization located in, resident in, formed under
the laws of, or owned or controlled by the government of, any Sanctioned Country, or (iv)&nbsp;any person, entity or organization made subject or target of any sanctions administered or enforced by the United States Government (including the US
Department of Treasury, Office of Foreign Assets Control and the US Department of State), including, without limitation, the list of Specially Designated Nationals (&#147;<B>SDN List</B>&#148;) of the Office of Foreign Assets Control of the U.S.
Treasury Department (&#147;<B>OFAC</B>&#148;), or by the United Nations Security Council, the European Union, His Majesty&#146;s <FONT STYLE="white-space:nowrap">Treasury-UK,</FONT> or other relevant sanctions authority (collectively,
&#147;<B>Sanctions</B>&#148;) and the Company will not directly or indirectly use the proceeds of this offering, or lend, contribute or otherwise make available such proceeds to any of its Subsidiaries, or any joint venture partner or other person
or entity, for the purpose of financing the activities of or business with any person, or in any country or territory, that currently is the subject to any U.S. sanctions administered by OFAC or in any other manner that will result in a violation by
any person (including any person participating in the transaction whether as underwriter, advisor, investor or otherwise) of U.S. sanctions administered by OFAC; (B)&nbsp;engaged in any transfers of goods, technologies or services (including
financial services) that may assist the governments of Sanctioned Countries or facilitate money laundering or other activities proscribed by United States laws, rules or regulations; (C)&nbsp;is a person, entity or organization currently the subject
of any Sanctions; or (D)&nbsp;located, organized or resident in any Sanctioned Country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(vv)</B> <B><I>Relationships with
Underwriters</I></B><I>. </I>The Company (i)&nbsp;does not have any material lending or other relationship with any bank or lending affiliate of any Underwriter and (ii)&nbsp;does not intend to use any of the proceeds from the sale of the Shares to
repay any outstanding debt owed to any affiliate of any Underwriter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any certificate signed by or on behalf of the Company and delivered
to the Representatives or to counsel for the Underwriters shall be deemed to be a representation and warranty by the Company to each Underwriter as to the matters covered thereby. The Company has a reasonable basis for making each of the
representations set forth in this Section&nbsp;1. The Company acknowledges that the Underwriters and, for purposes of the opinions to be delivered pursuant to Section&nbsp;6 hereof, counsel to the Company and counsel to the Underwriters, will rely
upon the accuracy and truthfulness of the foregoing representations and hereby consents to such reliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.</B>
<B>Purchase, Sale and Delivery of the Offered Shares</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><I>The Firm Shares</I></B>. Upon the terms herein set forth, the
Company agrees to issue and sell to the several Underwriters an aggregate of 18,750,000 Firm Shares. On the basis of the representations, warranties and agreements herein contained, and upon the terms but subject to the conditions herein set forth,
the Underwriters agree, severally and not jointly, to purchase from the Company the respective number of Firm Shares set forth opposite their names on <U>Schedule A</U>. The purchase price per Firm Share to be paid by the several Underwriters to the
Company shall be $3.008 per share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><I>The First Closing Date</I></B>. Delivery of the Firm Shares to be purchased
by the Underwriters and payment therefor shall be made at the offices of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (or such other place as may be agreed to by the Company and the Representatives) at 9:00 a.m., New York City time, on
July&nbsp;31, 2025, or such other time and date not later than 1:30 p.m., New York City time, on July&nbsp;31, 2025 as the Representatives shall designate by notice to the Company (the time and date of such closing are called the &#147;<B>First
Closing Date</B>&#148;). The Company hereby acknowledges that circumstances under which the Representatives may provide notice to postpone the First Closing Date as originally scheduled include, but are not limited to, any determination by the
Company or the Representatives to recirculate to the public copies of an amended or supplemented Prospectus or a delay as contemplated by the provisions of Section&nbsp;11. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B><I>The Optional Shares; Option Closing Date</I></B>. In addition, on the basis of the representations, warranties and agreements
herein contained, and upon the terms but subject to the conditions herein set forth, the Company hereby grants an option to the several Underwriters to purchase, severally and not jointly, up to an aggregate of 2,812,500 Optional Shares from the
Company at the purchase price per share to be paid by the Underwriters for the Firm Shares, less an amount per share equal to any dividend or distribution declared by the Company and payable on the Firm Shares but not payable on Optional Shares. The
option granted hereunder may be exercised at any time and from time to time in whole or in part upon notice by the Representatives to the Company, which notice may be given at any time within 30 days from the date of this Agreement. Such notice
shall set forth (i)&nbsp;the aggregate number of Optional Shares as to which the Underwriters are exercising the option and (ii)&nbsp;the time, date and place at which the Optional Shares will be delivered (which time and date may be simultaneous
with, but not earlier than, the First Closing Date; and in the event that such time and date are simultaneous with the First Closing Date, the term &#147;<B>First Closing Date</B>&#148; shall refer to the time and date of delivery of the Firm Shares
and such Optional Shares). Any such time and date of delivery, if subsequent to the First Closing Date, is called an &#147;<B>Option Closing Date</B>,&#148; and shall be determined by the Representatives and shall not be earlier than two or later
than five full business days after delivery of such notice of exercise. If any Optional Shares are to be purchased, each Underwriter agrees, severally and not jointly, to purchase the number of Optional Shares (subject to such adjustments to
eliminate fractional shares as the Representatives may determine) that bears the same proportion to the total number of Optional Shares to be purchased as the number of Firm Shares set forth on <U>Schedule A</U> opposite the name of such Underwriter
bears to the total number of Firm Shares. The Representatives may cancel the option at any time prior to its expiration by giving written notice of such cancellation to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B><I>Public Offering of the Offered Shares</I></B>. The Representatives hereby advise the Company that the Underwriters intend to
offer for sale to the public, initially on the terms set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus, their respective portions of the Offered Shares as soon after this Agreement has been executed as the
Representatives, in their sole judgment, have determined is advisable and practicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B><I>Payment for the Offered Shares</I></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Payment for the Offered Shares shall be made at the First Closing Date (and, if applicable, at each Option Closing Date) by wire transfer
of immediately available funds to the order of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) It is understood that the Representatives have been authorized, for
their own account and the accounts of the several Underwriters, to accept delivery of and receipt for, and make payment of the purchase price for, the Firm Shares and any Optional Shares the Underwriters have agreed to purchase. Each of Leerink
Partners and Guggenheim Securities, individually and not as the Representatives of the Underwriters, may (but shall not be obligated to) make payment for any Offered Shares to be purchased by any Underwriter whose funds shall not have been received
by the Representatives by the First Closing Date or the applicable Option Closing Date, as the case may be, for the account of such Underwriter, but any such payment shall not relieve such Underwriter from any of its obligations under this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B><I>Delivery of the Offered Shares</I></B>. The Company shall deliver, or cause to be delivered through the
facilities of The Depository Trust Company (&#147;<B>DTC</B>&#148;), unless the Representative shall otherwise instruct, to the Representatives for the accounts of the several Underwriters the Firm Shares at the First Closing Date, against release
of a wire transfer of immediately available funds for the amount of the purchase price therefor. The Company shall also deliver, or cause to be delivered through the facilities of DTC, unless the Representative shall otherwise instruct, to the
Representatives for the accounts of the several Underwriters, the Optional Shares the Underwriters have agreed to purchase at the First Closing Date or the applicable Option Closing Date, as the case may be, against the release of a wire transfer of
immediately available funds for the amount of the purchase price therefor. The Offered Shares shall be registered in such names and denominations as the Representatives shall have requested at least two full business days prior to the First Closing
Date (or the applicable Option Closing Date, as the case may be). Time shall be of the essence, and delivery at the time and place specified in this Agreement is a further condition to the obligations of the Underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.</B> <B>Additional Covenants of the Company</B>. The Company further covenants and agrees with each Underwriter as follows:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><I>Delivery of Registration Statement, Time of Sale Prospectus and Prospectus</I></B><I>. </I>The Company shall furnish,
upon request, to the Representatives in New York City, without charge, prior to 10:00 a.m., New York City time, on the second business day succeeding the date of this Agreement and during the period when a prospectus relating to the Offered Shares
is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) in connection with sales of the Offered Shares, as many copies of the Time of Sale Prospectus,
the Prospectus and any supplements and amendments thereto or to the Registration Statement as the Representatives may reasonably request. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><I>Representatives&#146; Review of Proposed Amendments and
Supplements</I></B><I>. </I>During the period when a prospectus relating to the Offered Shares is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule),
the Company (i)&nbsp;will furnish to the Representatives for review, a reasonable period of time prior to the proposed time of filing of any proposed amendment or supplement to the Registration Statement, a copy of each such amendment or supplement
and (ii)&nbsp;will not amend or supplement the Registration Statement (including any amendment or supplement through incorporation of any report filed under the Exchange Act) without the Representatives&#146; prior written consent, which consent
shall not be unreasonably withheld, conditioned or delayed. Prior to amending or supplementing any preliminary prospectus, the Time of Sale Prospectus or the Prospectus (including any amendment or supplement through incorporation of any report filed
under the Exchange Act), the Company shall furnish to the Representatives for review, a reasonable amount of time prior to the time of filing or use of the proposed amendment or supplement, a copy of each such proposed amendment or supplement. The
Company shall not file or use any such proposed amendment or supplement without the Representatives&#146; prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed. The Company shall file with the Commission
within the applicable period specified in Rule 424(b) under the Securities Act any prospectus required to be filed pursuant to such Rule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B><I>Free Writing Prospectuses</I></B><I>. </I>The Company shall furnish to the Representatives for review, a reasonable amount of
time prior to the proposed time of filing or use thereof, a copy of each proposed free writing prospectus or any amendment or supplement thereto prepared by or on behalf of, used by, or referred to by the Company, and the Company shall not file, use
or refer to any proposed free writing prospectus or any amendment or supplement thereto without the Representatives&#146; prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed. The Company shall furnish to
each Underwriter, without charge, as many copies of any free writing prospectus prepared by or on behalf of, used by or referred to by the Company as such Underwriter may reasonably request. If at any time when a prospectus is required by the
Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) in connection with sales of the Offered Shares (but in any event if at any time through and including the First
Closing Date) there occurred or occurs an event or development as a result of which any free writing prospectus prepared by or on behalf of, used by, or referred to by the Company conflicted or would conflict with the information contained in the
Registration Statement or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at such
time, not misleading, the Company shall promptly amend or supplement such free writing prospectus to eliminate or correct such conflict so that the statements in such free writing prospectus as so amended or supplemented will not include an untrue
statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at such time, not misleading, as the case may be; <I>provided, however</I>, that prior to
amending or supplementing any such free writing prospectus, the Company shall furnish to the Representatives for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of such proposed amended or supplemented
free writing prospectus, and the Company shall not file, use or refer to any such amended or supplemented free writing prospectus without the Representatives&#146; prior written consent, which consent shall not be unreasonably withheld, conditioned
or delayed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B><I>Filing of Underwriter Free Writing Prospectuses</I></B><I>. </I>The Company
shall not take any action that would result in an Underwriter or the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of such Underwriter that such
Underwriter otherwise would not have been required to file thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B><I>Amendments and Supplements to Time of Sale
Prospectus</I></B><I>. </I>If the Time of Sale Prospectus is being used to solicit offers to buy the Offered Shares at a time when the Prospectus is not yet available to prospective purchasers, and any event shall occur or condition exist as a
result of which it is necessary to amend or supplement the Time of Sale Prospectus so that the Time of Sale Prospectus does not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements
therein, in the light of the circumstances when delivered to a prospective purchaser, not misleading, or if any event shall occur or condition exist as a result of which the Time of Sale Prospectus conflicts with the information contained in the
Registration Statement, or if, in the opinion of counsel for the Underwriters, it is necessary to amend or supplement the Time of Sale Prospectus to comply with applicable law, the Company shall (subject to Section&nbsp;3(b) and Section&nbsp;3(c)
hereof) promptly prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to any dealer upon request, either amendments or supplements to the Time of Sale Prospectus so that the statements in the Time of Sale
Prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when delivered to a prospective
purchaser, not misleading or so that the Time of Sale Prospectus, as amended or supplemented, will no longer conflict with the information contained in the Registration Statement, or so that the Time of Sale Prospectus, as amended or supplemented,
will comply with applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B><I>Certain Notifications and Required Actions</I></B>. After the date of this Agreement,
the Company shall promptly advise the Representatives in writing (which may be by electronic mail) of: (i)&nbsp;the receipt of any comments of, or requests for additional or supplemental information from, the Commission; (ii)&nbsp;the time and date
of any filing of any post-effective amendment to the Registration Statement or any amendment or supplement to any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus or the Prospectus; (iii)&nbsp;the time and date that
any post-effective amendment to the Registration Statement becomes effective; and (iv)&nbsp;the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto or any
amendment or supplement to any preliminary prospectus, the Time of Sale Prospectus or the Prospectus or of any order preventing or suspending the use of any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus or the
Prospectus, or of any proceedings to remove, suspend or terminate from listing or quotation the Shares from any securities exchange upon which they are listed for trading or included or designated for quotation, or of the threatening or initiation
of any proceedings for any of such purposes. If the Commission shall enter any such stop order at any time, the Company will use its best efforts to obtain the lifting of such order at the earliest possible moment. Additionally, the Company agrees
that it shall comply with all applicable provisions of Rule 424(b), Rule 433 and Rule 430B under the Securities Act and will use its reasonable efforts to confirm that any filings made by the Company under Rule 424(b) or Rule 433 were received in a
timely manner by the Commission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> <B><I>Amendments and Supplements to the Prospectus and Other Securities Act
Matters</I></B><I>. </I>If any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Prospectus so that the Prospectus does not include an untrue statement of a material fact or omit to state a material
fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus is delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) to a purchaser, not
misleading, or if in the opinion of the Representatives or counsel for the Underwriters it is otherwise necessary to amend or supplement the Prospectus to comply with applicable law, the Company agrees (subject to Section&nbsp;3(b) and
Section&nbsp;3(c) hereof) to promptly prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to any dealer upon request, amendments or supplements to the Prospectus so that the statements in the Prospectus as so
amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus is delivered (whether
physically or through compliance with Rule 172 under the Securities Act or any similar rule) to a purchaser, not misleading or so that the Prospectus, as amended or supplemented, will comply with applicable law. Neither the Representatives&#146;
consent to, nor delivery of, any such amendment or supplement shall constitute a waiver of any of the Company&#146;s obligations under Section&nbsp;3(b) or Section&nbsp;3(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <B><I>Blue Sky Compliance</I></B>. The Company shall cooperate with the Representatives and counsel for the Underwriters to qualify
or register the Offered Shares for sale under (or obtain exemptions from the application of) the state securities or blue sky laws or Canadian provincial securities laws (or other foreign laws) of those jurisdictions reasonably designated by the
Representatives, shall comply with such laws and shall continue such qualifications, registrations and exemptions in effect so long as required for the distribution of the Offered Shares. The Company shall not be required to qualify as a foreign
corporation or to take any action that would subject it to general service of process in any such jurisdiction where it is not presently qualified or where it would be subject to taxation as a foreign corporation. The Company will advise the
Representatives promptly of the suspension of the qualification or registration of (or any such exemption relating to) the Offered Shares for offering, sale or trading in any jurisdiction or any initiation or threat of any proceeding for any such
purpose, and in the event of the issuance of any order suspending such qualification, registration or exemption, the Company shall use its reasonable efforts to obtain the withdrawal thereof at the earliest possible moment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B><I>Use of Proceeds</I></B>. The Company shall apply the net proceeds from the sale of the Offered Shares sold by it in the
manner described under the caption &#147;Use of Proceeds&#148; in the Registration Statement, the Time of Sale Prospectus and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> <B><I>Transfer Agent</I></B>. The Company shall engage and maintain, at its expense, a registrar and transfer agent for the Shares.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> <B><I>Earnings Statement</I></B>. The Company will make generally available to its security holders and to the Representatives
as soon as practicable an earnings statement (which need not be audited) covering a period of at least twelve months beginning with the first fiscal quarter of the Company commencing after the date of this Agreement that will satisfy the provisions
of Section&nbsp;11(a) of the Securities Act and the rules and regulations of the Commission thereunder, it being understood and agreed that such earning statement shall be deemed to have been made available by the Company if the Company is in
compliance with its reporting obligations pursuant to the Exchange Act, if such compliance satisfies the conditions of Rule 158, and if such earnings statement is made available on EDGAR. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> <B><I>Continued Compliance with Securities Laws</I></B>. The Company will comply
with the Securities Act and the Exchange Act so as to permit the completion of the distribution of the Offered Shares as contemplated by this Agreement<B>, </B>the Registration Statement, the Time of Sale Prospectus and the Prospectus. Without
limiting the generality of the foregoing, the Company will, during the period when a prospectus relating to the Offered Shares is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the
Securities Act or any similar rule), file on a timely basis with the Commission and Nasdaq all reports and documents required to be filed under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> <B><I>Listing</I></B>. The Company will use its best efforts to list, subject to notice of issuance, the Offered Shares on Nasdaq.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n)</B> <B><I>Company to Provide Copy of the Prospectus in Form That May be Downloaded from the Internet</I></B>. If requested by the
Representatives, the Company shall cause to be prepared and delivered, at its expense, within one business day from the effective date of this Agreement, to the Representatives an &#147;<B>electronic Prospectus</B>&#148; to be used by the
Underwriters in connection with the offering and sale of the Offered Shares. As used herein, the term &#147;<B>electronic Prospectus</B>&#148; means a form of Prospectus, and any amendment or supplement thereto, that meets each of the following
conditions: (i)&nbsp;it shall be encoded in an electronic format, satisfactory to the Representatives, that may be transmitted electronically by the Representatives and the other Underwriters to offerees and purchasers of the Offered Shares;
(ii)&nbsp;it shall disclose the same information as the paper Prospectus, except to the extent that graphic and image material cannot be disseminated electronically, in which case such graphic and image material shall be replaced in the electronic
Prospectus with a fair and accurate narrative description or tabular representation of such material, as appropriate; and (iii)&nbsp;it shall be in or convertible into a paper format or an electronic format, satisfactory to Leerink Partners, that
will allow investors to store and have continuously ready access to the Prospectus at any future time, without charge to investors (other than any fee charged for subscription to the Internet as a whole and for
<FONT STYLE="white-space:nowrap">on-line</FONT> time). The Company hereby confirms that it has included or will include in the Prospectus filed pursuant to EDGAR or otherwise with the Commission and in the Registration Statement at the time it was
declared effective an undertaking that, upon receipt of a request by an investor or his or her representative, the Company shall transmit or cause to be transmitted promptly, without charge, a paper copy of the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o)</B> <B><I>Agreement Not to Offer or Sell Additional Shares</I></B>. During the period commencing on and including the date hereof and
continuing through and including the 60th day following the date of the Prospectus (such period, as extended as described below, being referred to herein as the &#147;<B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period</B>&#148;), the Company
will not, without the prior written consent of the Representatives (which consent may be withheld in their sole discretion), directly or indirectly: (i)&nbsp;sell, offer to sell, contract to sell or lend any Shares or Related Securities (each as
defined below); (ii) effect any short sale, or establish or increase any &#147;put equivalent position&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">16a-1(h)</FONT> under the Exchange Act) or liquidate or decrease any &#147;call
equivalent position&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">16a-1(b)</FONT> under the Exchange Act) of any Shares or Related Securities; (iii)&nbsp;pledge any Shares or Related Securities; (iv)&nbsp;in any other way transfer or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
dispose of any Shares or Related Securities; (v)&nbsp;enter into any swap, hedge or similar arrangement or agreement that transfers, in whole or in part, the economic risk of ownership of any
Shares or Related Securities, regardless of whether any such transaction is to be settled in securities, in cash or otherwise; (vi)&nbsp;announce the offering of any Shares or Related Securities; (vii)&nbsp;submit or file any registration statement
under the Securities Act in respect of any Shares or Related Securities (other than as contemplated by this Agreement with respect to the Offered Shares); (viii) effect a reverse stock split, recapitalization, share consolidation, reclassification
or similar transaction affecting the outstanding Shares; or (ix)&nbsp;publicly announce the intention to do any of the foregoing; <I>provided, however</I>, that the Company may (A)&nbsp;effect the transactions contemplated hereby, (B)&nbsp;issue
shares of Common Stock upon the exercise of an option or warrant, the vesting of restricted stock units, performance stock units or deferred stock units or the conversion or exchange of a security outstanding on the date hereof as referred to in the
Registration Statement, the Time of Sale Prospectus and the Prospectus, (C)&nbsp;pursuant to the stock-based compensation plans of the Company and the Subsidiaries as referred to in the Registration Statement, the Time of Sale Prospectus and the
Prospectus, or pursuant to any qualifying inducement award under Nasdaq Listing Rule 5635(c)(4), (D) issue shares of Common Stock or other securities issued in connection with a transaction with an unaffiliated third party that includes a bona fide
commercial relationship (including joint ventures, marketing or distribution arrangements, collaboration agreements or intellectual property license agreements) or any acquisition of assets of not less than a majority or controlling portion of the
equity of another entity, <I>provided</I> that the aggregate number of shares of Common Stock that the Company may sell or issue or agree to sell or issue shall not exceed 5% of the total number of shares of Common Stock issued and outstanding
immediately following the issuance and sale of the Offered Shares pursuant to this Agreement, (E)&nbsp;file registration statements on Form <FONT STYLE="white-space:nowrap">S-8</FONT> or a successor form thereto relating to the shares of Common
Stock granted pursuant to or reserved for issuance under the stock-based compensation plans of the Company and the Subsidiary referred to in clause (C), (F) assist any stockholder of the Company in the establishment of a trading plan by such
stockholder pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the transfer of shares of Common Stock, <I>provided</I> that (1)&nbsp;such plan does not provide for the transfer of shares of Common Stock during
the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, (2)&nbsp;to the extent a public announcement or filing under the Exchange Act, if any, is required by or on behalf of the securityholders or the Company regarding the establishment of such
plan, such announcement or filing shall include a statement to the effect that no transfers by the securityholders may be made under such plan during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period and (3)&nbsp;such plan is otherwise
permitted to be implemented during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period pursuant to the terms of a <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement between such stockholder and the Underwriters in connection with the
offering contemplated by this Agreement, and (G)&nbsp;issue shares of Common Stock pursuant to the Sales Agreement, dated May&nbsp;9, 2024, between the Company and Guggenheim Securities, LLC, as sales agent. &#147;<B>Related Securities</B>&#148;
shall mean any options or warrants or other rights to acquire Shares or any securities exchangeable or exercisable for or convertible into Shares, or to acquire other securities or rights ultimately exchangeable or exercisable for, or convertible
into, Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(p)</B> <B><I>Future Reports to the Representatives</I></B><I>. </I>During the period of five years hereafter, the
Company will furnish to the Representatives, c/o Leerink Partners LLC, at 1301 Avenue of the Americas, 5th Floor, New York, New York 10019, Attention: Stuart R. Nayman and c/o Guggenheim Securities, LLC, 330 Madison Avenue, New York, New York 10017,
Attention: Head of Equity Capital Markets: (i)&nbsp;as soon as practicable after the end of each fiscal year, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
copies of the Annual Report of the Company containing the balance sheet of the Company as of the close of such fiscal year and statements of income, stockholders&#146;<I></I>&nbsp;equity and cash
flows for the year then ended and the opinion thereon of the Company&#146;s independent public or certified public accountants; (ii)&nbsp;as soon as practicable after the filing thereof, copies of each proxy statement, Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K,</FONT> Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> or other report filed by the Company with the Commission, FINRA or any
securities exchange; and (iii)&nbsp;as soon as available, copies of any report or communication of the Company furnished or made available generally to holders of its capital stock; <I>provided, however,</I> that the requirements of this
Section&nbsp;3(p) shall be satisfied to the extent that such reports, statement, communications, financial statements or other documents are available on EDGAR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(q)</B> <B><I>Investment Limitation</I></B>. The Company shall not invest or otherwise use the proceeds received by the Company from its
sale of the Offered Shares in such a manner as would require the Company or any of its subsidiaries to register as an investment company under the Investment Company Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(r)</B> <B><I>No Stabilization or Manipulation; Compliance with Regulation M</I></B>. The Company will not take, and will ensure that no
affiliate of the Company will take, directly or indirectly, any action designed to or that could reasonably be expected to cause or result in stabilization or manipulation of the price of the Shares or any reference security with respect to the
Shares, whether to facilitate the sale or resale of the Offered Shares or otherwise, and the Company will, and shall cause each of its affiliates to, comply with all applicable provisions of Regulation M. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(s)</B> <B><I>Enforce <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements</I></B>. During the
<FONT STYLE="white-space:nowrap">Lock-up</FONT> Period, the Company will enforce all agreements between the Company and any of its securityholders that restrict or prohibit, expressly or in operation, the offer, sale or transfer of Shares or Related
Securities or any of the other actions restricted or prohibited under the terms of the form of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement (each, a &#147;<B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</B>&#148;). In
addition, the Company will direct the transfer agent to place stop transfer restrictions upon any such securities of the Company that are bound by such <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements for the duration of the periods
contemplated in such agreements, including, without limitation, <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements entered into by the Company&#146;s executive officers and directors and certain securityholders pursuant to Section&nbsp;6(l)
hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(t)</B> <B><I>Company to Provide Interim Financial Statements</I></B>. Prior to the First Closing Date and each applicable
Option Closing Date, the Company will furnish the Underwriters, as soon as they have been prepared by or are available to the Company, a copy of any unaudited interim financial statements of the Company for any period subsequent to the period
covered by the most recent financial statements appearing in the Registration Statement and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.</B>
<B>Payment of Expenses</B>. The Company agrees to pay all costs, fees and expenses incurred in connection with the performance of its obligations hereunder and in connection with the transactions contemplated hereby, including without limitation
(i)&nbsp;all expenses incident to the issuance and delivery of the Offered Shares (including all printing and engraving costs), (ii) all fees and expenses of the registrar and transfer agent of the Shares, (iii)&nbsp;all necessary issue, transfer
and other stamp taxes in connection with the issuance and sale of the Offered Shares to the Underwriters, (iv)&nbsp;all fees and expenses of the Company&#146;s counsel, independent public or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
certified public accountants and other advisors, (v)&nbsp;all costs and expenses incurred in connection with the preparation, printing, filing, shipping and distribution of the Registration
Statement (including financial statements, exhibits, schedules, consents and certificates of experts), the Time of Sale Prospectus, the Prospectus, each free writing prospectus prepared by or on behalf of, used by, or referred to by the Company, and
each preliminary prospectus, and all amendments and supplements thereto, and this Agreement, (vi)&nbsp;all filing fees, attorneys&#146; fees and expenses incurred by the Company or the Underwriters in connection with qualifying or registering (or
obtaining exemptions from the qualification or registration of) all or any part of the Offered Shares for offer and sale under the state securities or blue sky laws or the provincial securities laws of Canada, and, if requested by the
Representatives, preparing and printing a &#147;Blue Sky Survey&#148; or memorandum and a &#147;Canadian wrapper&#148;, and any supplements thereto, advising the Underwriters of such qualifications, registrations and exemptions, (vii)&nbsp;the
costs, fees and expenses incurred by the Underwriters in connection with determining their compliance with the rules and regulations of FINRA related to the Underwriters&#146; participation in the offering and distribution of the Offered Shares,
including any related filing fees and the legal fees of, and disbursements by, counsel to the Underwriters; <I>provided,</I> <I>however</I>, that such legal fees, taken together with the legal fees described in clause (vi)&nbsp;above, shall not
exceed $50,000 in the aggregate, (viii)&nbsp;the costs and expenses of the Company relating to investor presentations on any &#147;road show&#148;, including, without limitation, expenses associated with the preparation or dissemination of any
electronic road show, expenses associated with the production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations with the prior approval of the Company, travel and lodging
expenses of the representatives, employees and officers of the Company and any such consultants (it being understood that the Underwriters will pay or cause to be paid the travel and lodging expenses of their representatives), and one half of the
cost of any aircraft chartered in connection with the road show (the remaining half of the cost to be paid by the Underwriters), (ix) the fees and expenses associated with listing the Offered Shares on Nasdaq, and (x)&nbsp;all other fees, costs and
expenses of the nature referred to in Item 14 of Part II of the Registration Statement; <I>provided,</I> that any expenses payable under clauses (vi)&nbsp;and (vii) above and any expenses relating to the one half of the cost of any aircraft
chartered in connection with the road show described in clause (viii)&nbsp;above are invoiced in a reasonably timely manner. Except as provided in this Section&nbsp;4 or in Section&nbsp;7, Section&nbsp;9 or Section&nbsp;10 hereof, the Underwriters
shall pay their own expenses, including the fees and disbursements of their counsel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.</B> <B>Covenant of the
Underwriters</B>. Each Underwriter severally and not jointly covenants with the Company not to take any action that would result in the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free
writing prospectus prepared by or on behalf of such Underwriter that otherwise would not, but for such actions, be required to be filed by the Company under Rule 433(d). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6.</B> <B>Conditions of the Obligations of the Underwriters</B>. The respective obligations of the several Underwriters
hereunder to purchase and pay for the Offered Shares as provided herein on the First Closing Date and, with respect to the Optional Shares, each Option Closing Date, shall be subject to the accuracy of the representations and warranties on the part
of the Company set forth in Section&nbsp;1 hereof as of the date hereof and as of the First Closing Date as though then made and, with respect to the Optional Shares, as of each Option Closing Date as though then made, to the timely performance by
the Company of its covenants and other obligations hereunder, and to each of the following additional conditions: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><I>Comfort Letter</I></B>. On the date hereof, the Representatives shall have
received from PricewaterhouseCoopers LLP, independent registered public accountants for the Company, a letter dated the date hereof addressed to the Underwriters, in form and substance satisfactory to the Representatives, containing statements and
information of the type ordinarily included in accountant&#146;s &#147;comfort letters&#148; to underwriters, delivered according to Statement of Auditing Standards No.&nbsp;72 (or any successor bulletin), with respect to the audited and unaudited
financial statements and certain financial information contained in the Registration Statement, the Time of Sale Prospectus, and each free writing prospectus, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><I>Compliance with Registration Requirements; No Stop Order; No Objection from FINRA</I></B><I>. </I>For the period from and
after the date of this Agreement and through and including the First Closing Date and, with respect to any Optional Shares purchased after the First Closing Date, each Option Closing Date: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) The Company shall have filed the Prospectus with the Commission (including the information previously omitted from the Registration
Statement pursuant to Rule&nbsp;430B under the Securities Act) in the manner and within the time period required by Rule&nbsp;424(b) under the Securities Act; or the Company shall have filed a post-effective amendment to the Registration Statement
containing the information previously omitted from the Registration Statement pursuant to such Rule 430B, and such post-effective amendment shall have become effective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) No stop order suspending the effectiveness of the Registration Statement or any post-effective amendment to the Registration Statement
shall be in effect, and no proceedings for such purpose shall have been instituted or threatened by the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) If a filing has
been made with FINRA, FINRA shall have raised no objection to the fairness and reasonableness of the underwriting terms and arrangements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B><I>No Material Adverse Effect or Ratings Agency Change</I></B>. For the period from and after the date of this Agreement and
through and including the First Closing Date and, with respect to any Optional Shares purchased after the First Closing Date, each Option Closing Date: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) in the judgment of the Representatives there shall not have occurred any Material Adverse Effect; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) there shall be no debt securities issued or guaranteed by the Company or any of its Subsidiaries by any &#147;nationally recognized
statistical rating organization&#148; as that term is used in Rule <FONT STYLE="white-space:nowrap">15c3-1(c)(2)(vi)(F)</FONT> under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B><I>Opinion of Counsel for the Company</I></B>. On each of the First Closing Date and each Option Closing Date the
Representatives shall have received the opinion and negative assurance letter of Goodwin Procter LLP, counsel for the Company, dated as of such date, in form and substance reasonably satisfactory to the Representatives. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B><I>Opinion of Hyman, Phelps</I></B><B><I></I></B><B><I>&nbsp;&amp; McNamara,
P.C</I></B>. On each of the First Closing Date and each Option Closing Date, the Representatives shall have received the opinion of Hyman, Phelps&nbsp;&amp; McNamara, P.C., regulatory counsel for the Company, dated as of such date, in form and
substance reasonably satisfactory to the Representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B><I>Opinion of McCarter</I></B><B><I></I></B><B><I>&nbsp;&amp;
English, LLP</I></B><I>. </I>On each of the First Closing Date and each Option Closing Date, the Representatives shall have received the opinion of McCarter&nbsp;&amp; English, LLP, intellectual property counsel for the Company, dated as of such
date, in form and substance reasonably satisfactory to the Representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> <B><I>Opinion of Counsel for the
Underwriters</I></B>. On each of the First Closing Date and each Option Closing Date the Representatives shall have received the opinion and negative assurance letter of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel for the
Underwriters in connection with the offer and sale of the Offered Shares, dated as of such date, in form and substance reasonably satisfactory to the Representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <B><I>Officers&#146; Certificate</I></B>. On each of the First Closing Date and each Option Closing Date, the Representatives shall
have received a certificate executed by the Chief Executive Officer or President of the Company and the Chief Financial Officer of the Company, dated as of such date, to the effect set forth in Section&nbsp;6(b)(ii) and further to the effect that:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) for the period from and including the date of this Agreement through and including such date, there has not occurred any Material
Adverse Effect; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) the representations, warranties and covenants of the Company set forth in Section&nbsp;1 of this Agreement are true
and correct with the same force and effect as though expressly made on and as of such date; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) the Company has complied with all
the agreements hereunder and satisfied all the conditions on its part to be performed or satisfied hereunder at or prior to such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B><I>Bring-down Comfort Letter</I></B>. On each of the First Closing Date and each Option Closing Date the Representatives shall
have received from PricewaterhouseCoopers LLP, independent registered public accountants for the Company, a letter dated such date, in form and substance satisfactory to the Representatives, which letter shall: (i)&nbsp;reaffirm the statements made
in the letter furnished by them pursuant to Section&nbsp;6(a), except that the specified date referred to therein for the carrying out of procedures shall be no more than three business days prior to the First Closing Date or the applicable Option
Closing Date, as the case may be; and (ii)&nbsp;cover certain financial information contained in the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> <B><I><FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Agreements</I></B><I>. </I>On or prior to the date hereof, the Company shall have furnished to the Representatives an agreement in the form of <U>Exhibit B</U> hereto from each of the persons listed on
<U>Exhibit C</U> hereto, and each such agreement shall be in full force and effect on each of the First Closing Date and each Option Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> <B><I>Rule 462(b) Registration Statement</I></B>. In the event that a Rule 462(b) Registration Statement is filed in connection
with the offering contemplated by this Agreement, such Rule&nbsp;462(b) Registration Statement shall have been filed with the Commission on the date of this Agreement and shall have become effective automatically upon such filing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> <B><I>CFO Certificate</I></B>. On the date of this Agreement and on the First
Closing Date or the applicable Option Closing Date, as the case may be, the Company shall have furnished to the Representatives a certificate, dated the respective dates of delivery thereof and addressed to the Underwriters, of its Chief Financial
Officer with respect to certain financial data contained in the Time of Sale Prospectus and the Prospectus, providing &#147;management comfort&#148; with respect to such information, in form and substance reasonably satisfactory to the
Representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> <B><I>Approval of Listing</I></B><I>.</I> On or before the First Closing Date, the Company shall have made
all required submissions to Nasdaq regarding the Offered Shares and shall have not received any notice objecting to the listing of the Offered Shares from Nasdaq. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n)</B> <B><I>Additional Documents</I></B>. On or before each of the First Closing Date and each Option Closing Date, the Representatives
and counsel for the Underwriters shall have received such information, documents and opinions as they may reasonably request for the purposes of enabling them to pass upon the issuance and sale of the Offered Shares as contemplated herein, or in
order to evidence the accuracy of any of the representations and warranties, or the satisfaction of any of the conditions or agreements, herein contained; and all proceedings taken by the Company in connection with the issuance and sale of the
Offered Shares as contemplated herein and in connection with the other transactions contemplated by this Agreement shall be satisfactory in form and substance to the Representatives and counsel for the Underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any condition specified in this Section&nbsp;6 is not satisfied when and as required to be satisfied, this Agreement may be terminated by
the Representatives by notice from Leerink Partners to the Company at any time on or prior to the First Closing Date and, with respect to the Optional Shares, at any time on or prior to the applicable Option Closing Date, which termination shall be
without liability on the part of any party to any other party, except that Section&nbsp;4, Section&nbsp;7, Section&nbsp;9 and Section&nbsp;10 shall at all times be effective and shall survive such termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.</B> <B>Reimbursement of Underwriters&#146; Expenses</B>. If this Agreement is terminated by the Representatives pursuant to
Section&nbsp;6, Section&nbsp;11 or Section&nbsp;12, or if the sale to the Underwriters of the Offered Shares on the First Closing Date is not consummated because of any refusal, inability or failure on the part of the Company to perform any
agreement herein or to comply with any provision hereof, the Company agrees to reimburse the Representatives and the other Underwriters (or such Underwriters as have terminated this Agreement with respect to themselves), severally, upon demand for
all <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses that shall have been reasonably incurred by the Representatives and the Underwriters in connection with the proposed purchase and the offering
and sale of the Offered Shares, including, but not limited to, fees and disbursements of counsel, printing expenses, travel expenses, postage, facsimile and telephone charges. For the avoidance of doubt, it is understood that the Company will not
pay or reimburse any costs, fees or expenses incurred by an Underwriter that defaults on its obligation to purchase the Offered Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.</B> <B>Effectiveness of this Agreement</B>. This Agreement shall become
effective upon the execution and delivery hereof by the parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;9.</B> <B>Indemnification</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B><I>Indemnification of the Underwriters</I></B>. The Company agrees to indemnify and hold harmless each Underwriter, its
affiliates, directors, officers, employees and agents, and each person, if any, who controls any Underwriter within the meaning of the Securities Act or the Exchange Act against any loss, claim, damage, liability or expense, as incurred, to which
such Underwriter or such affiliate, director, officer, employee, agent or controlling person may become subject, under the Securities Act, the Exchange Act, other federal or state statutory law or regulation, or the laws or regulations of foreign
jurisdictions where Offered Shares have been offered or sold or at common law or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of the Company), insofar as such loss, claim, damage,
liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment thereto,
or the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading; or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact included
in any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433(d) of the Securities Act, any Marketing Material or the Prospectus
(or any amendment or supplement to the foregoing), or the omission or alleged omission to state therein a material fact necessary in order to make the statements, in the light of the circumstances under which they were made, not misleading; or
(iii)&nbsp;any act or failure to act or any alleged act or failure to act by any Underwriter in connection with, or relating in any manner to, the Shares or the offering contemplated hereby, and which is included as part of or referred to in any
loss, claim, damage, liability or action arising out of or based upon any matter covered by clause (i)&nbsp;or (ii) above; and to reimburse each Underwriter and each such affiliate, director, officer, employee, agent and controlling person for any
and all reasonable expenses (including the reasonable fees and disbursements of counsel) as such expenses are incurred by such Underwriter or such affiliate, director, officer, employee, agent or controlling person in connection with investigating,
defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action; <I>provided, however</I>, that the foregoing indemnity agreement shall not apply to any loss, claim, damage, liability or expense to the extent,
but only to the extent, arising out of or based upon any untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company by
the Representatives in writing expressly for use in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, any such free writing prospectus, any Marketing Material or the Prospectus (or any amendment or supplement
thereto), it being understood and agreed that the only such information consists of the information described in Section&nbsp;9(b) below. The indemnity agreement set forth in this Section&nbsp;9(a) shall be in addition to any liabilities that the
Company may otherwise have. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><I>Indemnification of the Company, its Directors and Officers</I></B>. Each
Underwriter agrees, severally and not jointly, to indemnify and hold harmless the Company, each of its directors, each of its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of the
Securities Act or the Exchange Act, against any loss, claim, damage, liability or expense, as incurred, to which the Company, or any such director, officer or controlling person may become subject, under the Securities Act, the Exchange Act, or
other federal or state statutory law or regulation, or at common law or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of such Underwriter), insofar as such loss, claim, damage,
liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment thereto,
or any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact included
in any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433 of the Securities Act or the Prospectus (or any such amendment or
supplement) or the omission or alleged omission to state therein a material fact necessary in order to make the statements, in the light of the circumstances under which they were made, not misleading, in each case to the extent, but only to the
extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made in the Registration Statement, such preliminary prospectus, the Time of Sale Prospectus, such free writing prospectus or the Prospectus (or any
such amendment or supplement), in reliance upon and in conformity with information relating to such Underwriter furnished to the Company by the Representatives in writing expressly for use therein; and to reimburse the Company, or any such director,
officer or controlling person for any and all reasonable expenses (including the reasonable fees and disbursements of counsel) as such expenses are incurred by the Company, or any such director, officer or controlling person in connection with
investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action. The Company hereby acknowledges that the only information that the Representatives have furnished to the Company expressly for use
in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) of the Securities Act or the Prospectus (or any amendment
or supplement to the foregoing) are the statements set forth in (i)&nbsp;the sentences and figure relating to selling concession appearing in the first paragraph under the heading &#147;Underwriting&#151;Discounts and Commissions&#148; and
(ii)&nbsp;the statements concerning the Underwriters contained in the second and third paragraphs under the heading &#147;Underwriting&#151;Price Stabilization, Short Positions and Penalty Bids.&#148; each under the caption &#147;Underwriting&#148;
in the Preliminary Prospectus Supplement and the Final Prospectus Supplement. The indemnity agreement set forth in this Section&nbsp;9(b) shall be in addition to any liabilities that each Underwriter may otherwise have. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B><I>Notifications and Other Indemnification Procedures</I></B>. Promptly after receipt by an indemnified party under this
Section&nbsp;9 of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against an indemnifying party under this Section&nbsp;9, notify the indemnifying party in writing of the
commencement thereof, but the omission to so notify the indemnifying party will not relieve the indemnifying party from any liability which it may have to any indemnified party to the extent the indemnifying party is not materially prejudiced as a
proximate result of such failure and shall not in any event relieve the indemnifying party from any liability that it may have otherwise than on account of this indemnity agreement. In case any such action is brought against any indemnified party
and such indemnified party seeks or intends to seek indemnity from an indemnifying party, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
indemnifying party will be entitled to participate in, and, to the extent that it shall elect, jointly with all other indemnifying parties similarly notified, by written notice delivered to the
indemnified party promptly after receiving the aforesaid notice from such indemnified party, to assume the defense thereof with counsel reasonably satisfactory to such indemnified party; <I>provided, however</I>, that if the defendants in any such
action include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded that a conflict may arise between the positions of the indemnifying party and the indemnified party in conducting the
defense of any such action or that there may be legal defenses available to it and/or other indemnified parties which are different from or additional to those available to the indemnifying party, the indemnified party or parties shall have the
right to select separate counsel to assume such legal defenses and to otherwise participate in the defense of such action on behalf of such indemnified party or parties. Upon receipt of notice from the indemnifying party to such indemnified party of
such indemnifying party&#146;s election to so assume the defense of such action and approval by the indemnified party of counsel, the indemnifying party will not be liable to such indemnified party under this Section&nbsp;9 for any legal or other
expenses subsequently incurred by such indemnified party in connection with the defense thereof unless (i)&nbsp;the indemnified party shall have employed separate counsel in accordance with the proviso to the preceding sentence (it being understood,
however, that the indemnifying party shall not be liable for the fees and expenses of more than one separate counsel (together with one local counsel in each relevant jurisdiction), representing the indemnified parties who are parties to such
action), which counsel (together with one local counsel in each relevant jurisdiction) for the indemnified parties shall be selected by Leerink Partners (in the case of counsel for the indemnified parties referred to in Section&nbsp;9(a) above) or
by the Company (in the case of counsel for the indemnified parties referred to in Section&nbsp;9(b) above) or (ii)&nbsp;the indemnifying party shall not have employed counsel satisfactory to the indemnified party to represent the indemnified party
within a reasonable time after notice of commencement of the action or (iii)&nbsp;the indemnifying party has authorized in writing the employment of counsel for the indemnified party at the expense of the indemnifying party, in each of which cases
the fees and expenses of counsel shall be at the expense of the indemnifying party and shall be paid as they are incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>
<B><I>Settlements</I></B>. The indemnifying party under this Section&nbsp;9 shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the
plaintiff, the indemnifying party agrees to indemnify the indemnified party against any loss, claim, damage, liability or expense by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an indemnified party
shall have requested an indemnifying party to reimburse the indemnified party for the reasonable and documented fees and expenses of counsel as contemplated by Section&nbsp;9(c) hereof, the indemnifying party shall be liable for any settlement of
any proceeding effected without its written consent if (i)&nbsp;such settlement is entered into more than 30 days after receipt by such indemnifying party of the aforesaid request and (ii)&nbsp;such indemnifying party shall not have reimbursed the
indemnified party in accordance with such request prior to the date of such settlement. No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement, compromise or consent to the entry of judgment in
any pending or threatened action, suit or proceeding in respect of which any indemnified party is or could have been a party and indemnity was or could have been sought hereunder by such indemnified party, unless such settlement, compromise or
consent includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such action, suit or proceeding and does not include an admission of fault or culpability or a failure to act by or on
behalf of such indemnified party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;10.</B> <B>Contribution</B>. If the indemnification provided for in
Section&nbsp;9 is for any reason held to be unavailable to or otherwise insufficient to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities or expenses referred to therein, then each indemnifying party shall
contribute to the aggregate amount paid or payable by such indemnified party, as incurred, as a result of any losses, claims, damages, liabilities or expenses referred to therein (i)&nbsp;in such proportion as is appropriate to reflect the relative
benefits received by the Company, on the one hand, and the Underwriters, on the other hand, from the offering of the Offered Shares pursuant to this Agreement or (ii)&nbsp;if the allocation provided by clause (i)&nbsp;above is not permitted by
applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i)&nbsp;above but also the relative fault of the Company, on the one hand, and the Underwriters, on the other hand, in connection
with the statements or omissions which resulted in such losses, claims, damages, liabilities or expenses, as well as any other relevant equitable considerations. The relative benefits received by the Company, on the one hand, and the Underwriters,
on the other hand, in connection with the offering of the Offered Shares pursuant to this Agreement shall be deemed to be in the same respective proportions as the total proceeds from the offering of the Offered Shares pursuant to this Agreement
(before deducting expenses) received by the Company, and the total underwriting discounts and commissions received by the Underwriters, in each case as set forth on the front cover page of the Prospectus, bear to the aggregate initial public
offering price of the Offered Shares as set forth on such cover. The relative fault of the Company, on the one hand, and the Underwriters, on the other hand, shall be determined by reference to, among other things, whether any such untrue or alleged
untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company, on the one hand, or the Underwriters, on the other hand, and the parties&#146; relative intent, knowledge,
access to information and opportunity to correct or prevent such statement or omission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount paid or payable by a party as a result
of the losses, claims, damages, liabilities and expenses referred to above shall be deemed to include, subject to the limitations set forth in Section&nbsp;9(c), any legal or other fees or expenses reasonably incurred by such party in connection
with investigating or defending any action or claim. The provisions set forth in Section&nbsp;9(c) with respect to notice of commencement of any action shall apply if a claim for contribution is to be made under this Section&nbsp;10; <I>provided,
however,</I> that no additional notice shall be required with respect to any action for which notice has been given under Section&nbsp;9(c) for purposes of indemnification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to this Section&nbsp;10 were
determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which does not take account of the equitable considerations referred to in this Section&nbsp;10. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the provisions of this Section&nbsp;10, no Underwriter shall be required to
contribute any amount in excess of the underwriting discounts and commissions received by such Underwriter in connection with the Offered Shares underwritten by it and distributed to the public. No person guilty of fraudulent misrepresentation
(within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters&#146; obligations to contribute pursuant to this
Section&nbsp;10 are several, and not joint, in proportion to their respective underwriting commitments as set forth opposite their respective names on <U>Schedule A</U>. For purposes of this Section&nbsp;10, each affiliate, director, officer,
employee and agent of an Underwriter and each person, if any, who controls an Underwriter within the meaning of the Securities Act or the Exchange Act shall have the same rights to contribution as such Underwriter, and each director of the Company,
each officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of the Securities Act and the Exchange Act shall have the same rights to contribution as the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;11.</B> <B>Default of One or More of the Several Underwriters</B><I>. </I>If, on the First Closing Date or any Option Closing
Date any one or more of the several Underwriters shall fail or refuse to purchase Offered Shares that it or they have agreed to purchase hereunder on such date, and the aggregate number of Offered Shares which such defaulting Underwriter or
Underwriters agreed but failed or refused to purchase does not exceed 10% of the aggregate number of the Offered Shares to be purchased on such date, the Representatives may make arrangements satisfactory to the Company for the purchase of such
Offered Shares by other persons, including any of the Underwriters, but if no such arrangements are made by such date, the other Underwriters shall be obligated, severally and not jointly, in the proportions that the number of Firm Shares set forth
opposite their respective names on <U>Schedule A</U> bears to the aggregate number of Firm Shares set forth opposite the names of all such <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters, or in such other proportions as may be
specified by the Representatives with the consent of the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters, to purchase the Offered Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase
on such date. If, on the First Closing Date or any Option Closing Date any one or more of the Underwriters shall fail or refuse to purchase Offered Shares and the aggregate number of Offered Shares with respect to which such default occurs exceeds
10% of the aggregate number of Offered Shares to be purchased on such date, and arrangements satisfactory to the Representatives and the Company for the purchase of such Offered Shares are not made within 48 hours after such default, this Agreement
shall terminate without liability of any party to any other party except that the provisions of Section&nbsp;4, Section&nbsp;7, Section&nbsp;9 and Section&nbsp;10 shall at all times be effective and shall survive such termination. In any such case
either the Representatives or the Company shall have the right to postpone the First Closing Date or the applicable Option Closing Date, as the case may be, but in no event for longer than seven days in order that the required changes, if any, to
the Registration Statement and the Prospectus or any other documents or arrangements may be effected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this Agreement, the term
&#147;<B>Underwriter</B>&#148; shall be deemed to include any person substituted for a defaulting Underwriter under this Section&nbsp;11. Any action taken under this Section&nbsp;11 shall not relieve any defaulting Underwriter from liability in
respect of any default of such Underwriter under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;12.</B> <B>Termination of this
Agreement</B><I>. </I>Prior to the purchase of the Firm Shares by the Underwriters on the First Closing Date, this Agreement may be terminated by the Representatives by notice given to the Company if at any time: (i)&nbsp;trading or quotation in any
of the Company&#146;s securities shall have been suspended or limited by the Commission or by Nasdaq, or trading in securities generally on either Nasdaq or the NYSE shall have been suspended or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
limited, or minimum or maximum prices shall have been generally established on any of such stock exchanges; (ii)&nbsp;a general banking moratorium shall have been declared by any of federal, New
York, or Pennsylvania authorities; (iii)&nbsp;there shall have occurred any outbreak or escalation of national or international hostilities or any crisis or calamity, or any change in the United States or international financial markets, or any
substantial change or development involving a prospective substantial change in United States&#146; or international political, financial or economic conditions, as in the judgment of the Representatives is material and adverse and makes it
impracticable to market the Offered Shares in the manner and on the terms described in the Time of Sale Prospectus or the Prospectus or to enforce contracts for the sale of securities; (iv)&nbsp;in the judgment of the Representatives there shall
have occurred a Material Adverse Effect; or (v)&nbsp;the Company shall have sustained a loss by strike, fire, flood, earthquake, accident or other calamity of such character as in the judgment of the Representatives may interfere materially with the
conduct of the business and operations of the Company regardless of whether or not such loss shall have been insured. Any termination pursuant to this Section&nbsp;12 shall be without liability on the part of (a)&nbsp;the Company to any Underwriter,
except that the Company shall be obligated to reimburse the accountable and actually incurred expenses of the Representatives and the Underwriters pursuant to Section&nbsp;4 or Section&nbsp;7 hereof or (b)&nbsp;any Underwriter to the Company;
<I>provided, however,</I> that the provisions of Section&nbsp;9 and Section&nbsp;10 shall at all times be effective and shall survive such termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;13.</B> <B>No Advisory or Fiduciary Relationship</B>. The Company acknowledges and agrees that (a)&nbsp;the purchase and sale of
the Offered Shares pursuant to this Agreement, including the determination of the public offering price of the Offered Shares and any related discounts and commissions, is an <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> commercial
transaction between the Company, on the one hand, and the several Underwriters, on the other hand, and does not constitute a recommendation, investment advice, or solicitation of any action by the Underwriters, (b)&nbsp;in connection with the
offering contemplated hereby and the process leading to such transaction, each Underwriter is and has been acting solely as a principal and is not the agent or fiduciary of the Company, or its stockholders, creditors, employees or any other party,
(c)&nbsp;no Underwriter has assumed or will assume an advisory or fiduciary responsibility in favor of the Company with respect to the offering contemplated hereby or the process leading thereto (irrespective of whether such Underwriter has advised
or is currently advising the Company on other matters) and no Underwriter has any obligation to the Company with respect to the offering contemplated hereby except the obligations expressly set forth in this Agreement, (d)&nbsp;the Underwriters and
their respective affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Company, (e)&nbsp;the Underwriters have not provided any legal, accounting, regulatory or tax advice with respect to the
offering contemplated hereby and the Company has consulted its own legal, accounting, regulatory and tax advisors to the extent it deemed appropriate , and (f)&nbsp;none of the activities of the Underwriters in connection with the transactions
contemplated herein constitutes a recommendation, investment advice or solicitation of any action by the Underwriters with respect to any entity or natural person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;14.</B> <B>Representations and Indemnities to Survive Delivery</B><I>. </I>The respective indemnities, agreements,
representations, warranties and other statements of the Company, of its officers and of the several Underwriters set forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation made by or on
behalf of any Underwriter or the Company or any of its or their partners, officers or directors or any controlling person, as the case may be, and, anything herein to the contrary notwithstanding, will survive delivery of and payment for the Offered
Shares sold hereunder and any termination of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;15.</B> <B>Notices</B>. All communications hereunder shall be in writing and
shall be mailed, hand delivered or telecopied and confirmed to the parties hereto as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="77%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If to the Representatives:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Leerink Partners LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1301 Avenue of the Americas, 5th Floor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">New York, New York 10019</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: Stuart R. Nayman</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Guggenheim Securities, LLC</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">330 Madison
Avenue</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">New York, New York 10017</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: Head of Equity Capital Markets</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">with a copy to:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">One Financial Center</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Boston, MA 02111</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: William C. Hicks, John T. Rudy and Alok A. Choksi</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If to the Company:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Larimar Therapeutics, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Three Bala Plaza East, Suite 506</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Bala Cynwyd, Pennsylvania</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">with a copy to:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Goodwin Procter LLP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3025 John F Kennedy Blvd, 8th floor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Philadelphia, Pennsylvania 19104</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention: Jennifer Porter and Rachael Bushey</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any party hereto may change the address for receipt of communications by giving written notice to the others. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;16.</B> <B>Successors</B><I>. </I>This Agreement will inure to the benefit of and be binding upon the parties hereto, including
any substitute Underwriters pursuant to Section&nbsp;11 hereof, and to the benefit of the affiliates, directors, officers, employees, agents and controlling persons referred to in Section&nbsp;9 and Section&nbsp;10, and in each case their respective
successors, and personal representatives, and no other person will have any right or obligation hereunder. The term &#147;<B>successors</B>&#148; shall not include any purchaser of the Offered Shares as such from any of the Underwriters merely by
reason of such purchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;17.</B> <B>Partial Unenforceability</B>. The invalidity or unenforceability of any section,
paragraph or provision of this Agreement shall not affect the validity or enforceability of any other section, paragraph or provision hereof. If any section, paragraph or provision of this Agreement is for any reason determined to be invalid or
unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;18.</B> <B>Recognition of the U.S. Special Resolution Regimes</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> In the event that any Underwriter that is a Covered Entity (as defined below) becomes subject to a proceeding under a U.S. Special
Resolution Regime (as defined below), the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special
Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a
proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S.
Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. For purposes of this Agreement, (A) &#147;<B>BHC Act Affiliate</B>&#148; has the meaning assigned to the term
&#147;affiliate&#148; in, and shall be interpreted in accordance with, 12 U.S.C. &#167; 1841(k); (B) &#147;<B>Covered Entity</B>&#148; means any of the following: (i)&nbsp;a &#147;covered entity&#148; as that term is defined in, and interpreted in
accordance with, 12 C.F.R. &#167; 252.82(b); (ii) a &#147;covered bank&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or (iii)&nbsp;a &#147;covered FSI&#148; as that term is defined in, and
interpreted in accordance with, 12 C.F.R. &#167; 382.2(b); (C) &#147;<B>Default Right</B>&#148; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable; and
(D) &#147;<B>U.S. Special Resolution Regime</B>&#148; means each of (i)&nbsp;the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the
regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;19.</B> <B>Governing Law Provisions</B><I>. </I>This Agreement shall be governed by and
construed in accordance with the internal laws of the State of New York applicable to agreements made and to be performed in such state. Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions
contemplated hereby may be instituted in the federal courts of the United States of America located in the Borough of Manhattan in the City of New York or the courts of the State of New York in each case located in the Borough of Manhattan in the
City of New York (collectively, the &#147;<B>Specified Courts</B>&#148;), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a judgment of any such court, as to which
such jurisdiction is <FONT STYLE="white-space:nowrap">non-exclusive)</FONT> of such courts in any such suit, action or proceeding. Service of any process, summons, notice or document by mail to such party&#146;s address set forth above shall be
effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the Specified Courts
and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has been brought in an inconvenient forum. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;20.</B> <B>General Provisions</B>. This Agreement constitutes the entire
agreement of the parties to this Agreement and supersedes all prior written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof. This Agreement may be executed in two or more
counterparts, each one of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement may not be amended or modified unless in writing by all of the parties hereto, and no
condition herein (express or implied) may be waived unless waived in writing by each party whom the condition is meant to benefit. The section headings herein are for the convenience of the parties only and shall not affect the construction or
interpretation of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the parties hereto acknowledges that it is a sophisticated business person who was adequately
represented by counsel during negotiations regarding the provisions hereof, including, without limitation, the indemnification provisions of Section&nbsp;9 and the contribution provisions of Section&nbsp;10, and is fully informed regarding said
provisions. Each of the parties hereto further acknowledges that the provisions of Section&nbsp;9 and Section&nbsp;10 hereof fairly allocate the risks in light of the ability of the parties to investigate the Company, its affairs and its business in
order to assure that adequate disclosure has been made in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, each free writing prospectus and the Prospectus (and any amendments and supplements to the foregoing), as
contemplated by the Securities Act and the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[remainder of page intentionally left blank] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding of our agreement, kindly sign and
return to the Company the enclosed copies hereof, whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LARIMAR THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Michael Celano</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Michael Celano</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Underwriting Agreement</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing Underwriting Agreement is hereby confirmed and accepted by the Representatives
in New York, New York as of the date first above written. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LEERINK PARTNERS LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>GUGGENHEIM SECURITIES, LLC </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acting individually and as
Representatives of the several Underwriters named in the attached <U>Schedule A</U>. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LEERINK PARTNERS LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Jon A Civitarese</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Jon A Civitarese</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Senior Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>GUGGENHEIM SECURITIES, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Jordan Bliss</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Jordan Bliss</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Senior Managing Director</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Underwriting Agreement</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule A </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Underwriters</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Firm Shares<BR>to&nbsp;be&nbsp;Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Guggenheim Securities, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Truist Securities, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,875,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William Blair&nbsp;&amp; Company, L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,875,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule <FONT STYLE="white-space:nowrap">B-1</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Pricing Terms </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. The Company is
selling 18,750,000 Firm Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. The Company has granted an option to the Underwriters, severally and not jointly, to purchase up to 2,812,500 Optional
Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. The public offering price per share for the Offered Shares shall be $3.20. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule <FONT STYLE="white-space:nowrap">B-2</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Free Writing Prospectuses Included in the Time of Sale Prospectus </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">None. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule B-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Subsidiaries </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Zafgen Australia Pty Limited </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Form of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July ___, 2025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Guggenheim Securities, LLC </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representatives of the several
Underwriters </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c/o</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Leerink Partners LLC </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">53 State Street, 40th Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts 02109 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c/o</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Guggenheim Securities, LLC </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">330 Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">New York, New
York 10017 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Larimar Therapeutics, Inc. &#150; <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This letter
agreement (this &#147;<B>Agreement</B>&#148;) relates to the proposed offering (the &#147;<B>Offering</B>&#148;) by Larimar Therapeutics, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), of its common stock, $0.001 par value (the
&#147;<B>Stock</B>&#148;) and/or other equity securities of the Company, pursuant to an Underwriting Agreement (the &#147;<B>Underwriting Agreement</B>&#148;) to be entered into by and among the Company and Leerink Partners LLC and Guggenheim
Securities, LLC, as representatives (the &#147;<B>Representatives</B>&#148;) of the several underwriters named therein (the &#147;<B>Underwriters</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to induce you and the other Underwriters to underwrite the Offering, the undersigned hereby agrees that, without the prior written consent of the
Representatives, during the period from the date hereof until 90 days from the date of the final prospectus supplement for the Offering (the &#147;<B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period</B>&#148;), the undersigned will not
(a)&nbsp;directly or indirectly, offer, sell, agree to offer or sell, solicit offers to purchase, grant any call option or purchase any put option with respect to, pledge, borrow or otherwise dispose of, any Relevant Security (as defined below), (b)
establish or increase any &#147;put equivalent position&#148; or liquidate or decrease any &#147;call equivalent position&#148; with respect to any Relevant Security (in each case within the meaning of Section&nbsp;16 of the Securities Exchange Act
of 1934, as amended (the &#147;<B>Exchange Act</B>&#148;), and the rules and regulations promulgated thereunder), (c) otherwise enter into any swap, hedge, derivative or other transaction or arrangement that transfers to another, in whole or in
part, any economic consequence of ownership of a Relevant Security, whether or not such transaction is to be settled by delivery of Relevant Securities, other securities, cash or other consideration, or (d)&nbsp;publicly announce any intention to do
any of the foregoing. As used herein &#147;<B>Relevant Security</B>&#148; means the Stock, any other equity security of the Company or any of its subsidiaries and any security convertible into, or exercisable or exchangeable for, any Stock or other
such equity security. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit B-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing restrictions in this Agreement shall not apply to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the transfer of Relevant Securities (i)&nbsp;as a bona fide gift or gifts, (ii)&nbsp;by will, other
testamentary document or intestate succession, (iii)&nbsp;to a Family Member (as defined below), (iv) to a trust for the direct or indirect benefit of the undersigned and/or one or more Family Members, (v)&nbsp;by operation of law, including
pursuant to a domestic order, divorce settlement, divorce decree, separation agreement or pursuant to an order of a court of competent jurisdiction enforcing such agreement, (vi)&nbsp;to a charitable trust or (vii)&nbsp;if the undersigned is a
trust, to the beneficiary of such trust; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the transfer of Relevant Securities to the Company (i)&nbsp;as forfeitures to satisfy tax withholding
obligations of the undersigned existing as of the date of the final prospectus supplement in connection with the vesting or exercise of equity awards, (ii)&nbsp;pursuant to a net exercise or cashless exercise (to satisfy exercise price or related
withholding obligations) by the undersigned of outstanding equity awards existing as of the date of the final prospectus supplement, <I>provided</I> that any shares of Stock acquired upon the net exercise or cashless exercise of equity awards
described in this clause (b)&nbsp;shall be subject to the restrictions set forth in this Agreement, or (iii)&nbsp;by an executive officer upon death, disability or termination of employment, in each case, of such executive officer;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">distributions of Relevant Securities to limited partners, members or stockholders of the undersigned;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transactions relating to Relevant Securities acquired in the Offering or in open market transactions after the
closing of the Offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the transfer of Relevant Securities pursuant to a bona fide third-party tender offer for all outstanding shares
of the Company, merger, consolidation or other similar transaction made to all holders of the Company&#146;s securities involving a change of control of the Company (including, without limitation, the entering into of any <FONT
STYLE="white-space:nowrap">lock-up,</FONT> voting or similar agreement pursuant to which the undersigned may agree to transfer, sell, tender or otherwise dispose of Relevant Securities in connection with such transaction, or vote any Relevant
Securities in favor of any transaction), <I>provided</I> that in the event that such tender offer, merger, consolidation or other such transaction is not completed, such securities held by the undersigned shall remain subject to the provisions of
this Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the transfer of Relevant Securities to a corporation, limited liability company or partnership wholly owned by
the undersigned and/or one or more Family Members or to the undersigned&#146;s direct or indirect affiliates or to any investment fund or any manager thereof or other entity controlled or managed by, controlling or managing, or under common control
with, the undersigned (including, for the avoidance of doubt, where the undersigned is a partnership, to its general partner or a successor partnership or fund or any other funds managed by such partnership); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">pledges of Relevant Securities as collateral pursuant to a bona fide margin loan (including any subsequent
transfer upon foreclosure under any such pledge). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit B-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It shall be a further condition to any transfer or distribution pursuant to the preceding
clauses (a), (b), (c), (d) or (f)&nbsp;that no public disclosure or filing by any party (donor, donee, transferor or transferee) under the Exchange Act, or other public announcement shall be required or shall be made voluntarily in connection with
such transfer or distribution (other than a filing on Form 5 made after the expiration of the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period); <I>provided</I>, <I>however</I>, that in the case of any transfer or distribution pursuant to
clauses (a), (b), (c), (d) or (f), to the extent the undersigned is required to file a report under Section&nbsp;13 or Section&nbsp;16 of the Exchange Act, the undersigned shall be permitted to proceed with such transaction irrespective of such
filing requirement and file such report, <I>provided</I> the report clearly indicates in the footnotes or otherwise in the text disclosure thereto the nature of the transfer and no other public announcement shall be required or shall be made
voluntarily in connection with such transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It shall be a condition to any transfer or distribution pursuant to the preceding clause
(a)&nbsp;that (x) any such transfer shall not involve a disposition for value and (y)&nbsp;each resulting transferee or donee of Relevant Securities executes and delivers to you an agreement satisfactory to you in which such transferee agrees to be
bound by the terms of this Agreement for the remainder of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It shall be a
condition to any transfer or distribution pursuant to each of the preceding clauses (c), (f) or (g) (solely in the case of subsequent transfer upon foreclosure under any such pledge) that each resulting transferee or donee of Relevant Securities
executes and delivers to you an agreement satisfactory to you in which such transferee agrees to be bound by the terms of this Agreement for the remainder of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Agreement, the term &#147;<B>Family Member</B>&#148; shall mean any relationship by blood, domestic partnership, marriage
or adoption not more remote than first cousin. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the restrictions described in this Agreement shall not apply to the
establishment of a trading plan pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act, <I>provided</I> that no transfers occur under such plan during the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period and no
public announcement or filing shall be required or voluntarily made by any person in connection therewith other than general disclosure in Company periodic reports to the effect that the Company directors and officers may enter into such trading
plans from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby authorizes the Company during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period
to cause any transfer agent for the Relevant Securities to decline to transfer, and to note stop transfer restrictions on the stock register and other records relating to, Relevant Securities for which the undersigned is the record holder. The
undersigned hereby further agrees that, without the prior written consent of the Representatives, during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period the undersigned will not (x)&nbsp;file or participate in the filing with the U.S.
Securities and Exchange Commission (the &#147;<B>SEC</B>&#148;) of any registration statement, or circulate or participate in the circulation of any preliminary or final prospectus supplement or other disclosure document with respect to any proposed
offering or sale of a Relevant Security, (y)&nbsp;exercise any rights the undersigned may have to require registration with the SEC of any proposed offering or sale of a Relevant Security, or (z)&nbsp;publicly announce any intention to do any of the
foregoing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit B-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is understood that, if (i)&nbsp;the Company notifies the Underwriters that it does not
intend to proceed with the Offering, (ii)&nbsp;the Underwriting Agreement does not become effective, (iii)&nbsp;the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated prior to
payment for and delivery of the Stock, or (iv)&nbsp;the closing of the Offering pursuant to the Underwriting Agreement has not occurred by August&nbsp;15, 2025, the undersigned will be immediately and automatically released from its obligations
under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is further understood that if any party to a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement with
respect to the Company is formally or informally released or waived from any or all of its obligations thereunder (the &#147;<B>Released Party</B>&#148;), the undersigned will be similarly and contemporaneously released or waived from its
obligations hereunder (which for the avoidance of doubt will include a release or waiver of the same percentage of the shares of the Relevant Securities as was granted to the Released Party) and the Underwriters agree to provide notice thereof to
the undersigned at least three (3)&nbsp;business days prior thereto. Notwithstanding the foregoing, the provisions of this paragraph shall not apply if (1)&nbsp;the aggregate number of shares of Stock subject to releases or waivers granted by the
Representatives during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period represents less than or equal to 10% of the total number subject to such <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements (determined as of the date of the
closing of the Offering and giving effect to the Offering), or (2)&nbsp;the release or waiver is granted to a natural person due to circumstances of an emergency or hardship as determined by the Representatives in their sole judgment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned understands that the Company and the Underwriters will proceed with the Offering in reliance on this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether or not the Offering actually occurs depends on a number of factors, including market conditions. Any Offering will only be made
pursuant to the Underwriting Agreement, the terms of which are subject to negotiation between the Company and the Underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Agreement and that this Agreement constitutes the legal, valid and binding obligation of the undersigned, enforceable in accordance with
its terms. Upon request, the undersigned will execute any additional documents necessary in connection with enforcement hereof. Any obligations of the undersigned shall be binding upon the successors, heirs, personal representatives and assigns of
the undersigned from the date first above written. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Agreement shall be governed by and construed in accordance with the laws of the
State of New York. This letter agreement may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com or www.echosign.com) or other transmission
method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[remainder of page left intentionally blank] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit B-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name of Security Holder<I> (Print exact name)</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">If not signing in an individual capacity:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name of Authorized Signatory (<I>Print</I>)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title of Authorized Signatory (<I>Print</I>)</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(<I>indicate capacity of person signing if signing as custodian, trustee, or on behalf of an entity</I>) </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit B-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Directors, Executive Officers and Others </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Signing <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directors: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Carole S. <FONT STYLE="white-space:nowrap">Ben-Maimon,</FONT> M.D. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Thomas Hamilton </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Jonathan Leff </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Frank Thomas </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Joseph Truitt </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Jeffrey W. Sherman, M.D. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Michael Celano </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Gopi Shankar, Ph.D., MBA, FAAPS </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Russell Clayton, DO </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Others: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Entities affiliated with Deerfield Management </P></TD></TR></TABLE>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit C-1 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>d35960dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g35960g0730113425906.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwin Procter <SMALL>LLP</SMALL></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3025 John F
Kennedy Blvd Philadelphia, PA 19104</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">gooodwinlaw.com</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+1 445 207 7800</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">July&nbsp;29, 2025 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Larimar Therapeutics, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Three Bala Plaza East, Suite 506
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bala Cynwyd, PA 19004 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Securities Registered under Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT></U>
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as counsel to you in connection with your filing of a Registration Statement on Form
<FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-279275)</FONT> (as amended or supplemented, the &#147;Registration Statement&#148;) filed on May&nbsp;9, 2024 with the Securities and Exchange Commission
(the &#147;Commission&#148;) pursuant to the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), relating to the registration of the offer by Larimar Therapeutics, Inc., a Delaware corporation (the &#147;Company&#148;), of up to
$300,000,000 of any combination of securities of the types specified therein. The Registration Statement was declared effective by the Commission on May&nbsp;24, 2024. Reference is made to our opinion letter dated May&nbsp;9, 2024 and included as
Exhibit 5.1 to the Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are delivering this supplemental opinion letter in connection with the prospectus supplement (the
&#147;Prospectus Supplement&#148;) filed on July&nbsp;30, 2025 by the Company with the Commission pursuant to Rule 424 under the Securities Act. The Prospectus Supplement relates to the offering by the Company of up to 21,562,500 shares (the
&#147;Shares&#148;) of common stock, $0.001 par value per share (the &#147;Common Stock&#148;), of the Company covered by the Registration Statement. The Shares include an option granted to the underwriters to purchase up to an additional 2,812,500
Shares. The Shares are being sold to the several underwriters named in, and pursuant to, an underwriting agreement among the Company and such underwriters (the &#147;Underwriting Agreement&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have reviewed such documents and made such examination of law as we have deemed appropriate to give the opinion set forth below. We have relied, without
independent verification, on certificates of public officials and, as to matters of fact material to the opinion set forth below, on certificates of officers of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The opinion set forth below is limited to the Delaware General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the foregoing, we are of the opinion that the Shares have been duly authorized and, when delivered and paid for in accordance with the terms of the
Underwriting Agreement, will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our opinion set forth above is
subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and other similar laws of general application affecting the rights and remedies of creditors and to general principles of equity. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Larimar Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July&nbsp;29, 2025 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 2 </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion letter and the opinion it contains shall be interpreted in accordance with the Core Opinion
Principles as published in 74 <I>Business Lawyer</I> 815 (Summer 2019). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion is being furnished to you for submission to the Commission as an
exhibit to the Company&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (the &#147;Current Report&#148;) relating to the Shares, which is incorporated by reference in the Registration Statement. We hereby consent to the
inclusion of this opinion as Exhibit&nbsp;5.1 to the Current Report and to the references to our firm under the caption &#147;Legal Matters&#148; in the Prospectus Supplement. In giving our consent, we do not admit that we are in the category of
persons whose consent is required under Section&nbsp;7 of the Securities Act or the rules and regulations thereunder. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Goodwin Procter LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GOODWIN PROCTER <SMALL>LLP</SMALL></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>lrmr-20250729.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 7/31/2025 9:18:52 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2024"
  xmlns:lrmr="http://www.larimartx.com/20250729"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.larimartx.com/20250729"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" namespace="http://xbrl.sec.gov/naics/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lrmr-20250729_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lrmr-20250729_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.larimartx.com//20250729/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>lrmr-20250729_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 7/31/2025 9:18:52 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>lrmr-20250729_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 7/31/2025 9:18:52 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.larimartx.com//20250729/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="lrmr-20250729.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.larimartx.com//20250729/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g35960g0730113425906.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g35960g0730113425906.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  L ,@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#U_5_%VDZ1
ME);@2SC_ )91?,?Q[#\:X;4_'>HZAN2VQ:PG^X<L?Q_PKGY;2*8EA\K'N*[3
MPWX#M)K2"^OYFF$B[EB7Y5_$]37CJO4Q+Y8:'TOU7!X*'/5U9R=OJ$\,XFCF
MD67.=X;FNNTOQU/%MCOXQ,G_ #T3AORZ']*ZZ?0-*GM%MGL8?*4?*%7!7Z$<
MUR>H>"+2SD\\ZFMO9C[WG8R/H:7U:O0=Z;,GC,)B?=J1L_Z['8:=K%CJ:;K6
M=7(&2G1A]15^N"T'6O#]KK<&G:9!--)-E&NG^F>_;BN]KT:$W./O;^1Y&*H^
MRG9)I/:X445RWB7Q]HWAB3[/</)/=XSY$(!8?4]!6QSG4T5YS9_&'2);A8[V
MQO+-6Z2, P'UQS^6:] BNH)[1+N.56@=!(LF>"N,Y^F* )J*\^U/XN:+9W36
M]E;W-^5."\8"H?H3R?RK1\.?$?1?$5TMFOFVEXQPL4X WGT4C@GVX- '845%
M<W,-I;27%Q*D4,:EG=S@ #O7GM[\8='BN6BLK*[O$4\R* @/TSS^8% 'H]%<
MOX9\>:-XGD\BV=X;L#)@G #'W'8T[Q?XRM_"$=H\]I+<"Y+ "-@,8QZ_6@#I
MJ*\S7XS:=O'G:3>QIW8%3C\.*[73/$=AK>DR:AI4GVE44GRQ\K;@,[2#T- &
MO17-^$/&-KXNM[J2WMY+=K=PKQR$$\C@\?0_E53Q'X_L/#FO6VE3V\LKS*K-
M(C#$88XY_+- '7T53U/48M+TJZU";)CMXFD8#J<#I^-8.F>-8M1\)7GB$6,T
M4%OO(C9@6<*.<?R_"@#JJ*P= \31:_X=;6(K=XHUW_NV()^6J'A+Q]IWBR>:
MVBBDMKB,;A'*P)=>Y&/2@#K:*YSQ?XN@\(VMM<3VLEPL[E (V Q@9[T4 >4K
M+BO9?#ASX<L#_P!,17B"R9KVKPM-')X;L0KJS+$ P!Z'T->5@8\M1^A])G<;
M4X^IG^,/$-UH<4"6J(7G#?.W.W&.WXUYAJ&H7FI2^;>7$DS=MQX'T'05ZOXC
M\-CQ!):EKDPI#NW87)(..GY5SOBC0]%T;P\\4 C^V%EVL[9D;GG]*O$0J2DY
M-^ZC++<1AZ<8Q4;S9ROA ?\ %7:=_P!=#_Z":]MKQ7PB/^*MT_\ ZZ'^1KVJ
MML%\#,L\_CQ]/U([B0PV\D@&2BEL>N!7DOPKTRWUS4=3U_4E6YO%F&SS!G:S
M9);'KT ]*]=(R,&O(I]'\0_#OQ!<ZAHEFU]I%R<O"H)*C.0"!R",G#<\=:[#
MQ3JO$GB?P8MQ-I.N&.22(C=&]NS;3@$8('H>U4?B7JX3X=PRZ<Q6WOY(XPRC
M;^[*ENG;(4#'O7*:]K&I>-K=K*P\&F&YE93)=&/+C'^V5&/Q->B7?A7^U? %
MOH-VPCGCMHU#KR$D51@^XS^E "> ] L-)\+6$L$,9GN8$FFFP-S%AG&?09Q7
M+_%S1;2WT^VUVV5;>^CN%0O&-I<$$@GW!'6J.E>(_%?@6V&D:IH4U[;0G;!+
M'G 'H& ((]N"*;/:^)OB;J=L+RP?3-&@;<=X()]2,X+-C@<8% $OQ'UF[NO
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M=WYUM_#[0!8^ X[>ZB*O>AY)D88.&X /_ 0* .6\4^)VO_A1I*(Q:ZU K!(
M>3Y?WOS(7\ZZK4=*71/A/=:> -T.GL'([N1EC^9->=^$_#.I2>.+73+V&?[#
MIEQ)*"R$)E2.AZ<D+7K?C&-Y?!NKQQHSNUJX55&23B@#F?AQ_P DRE^L_P#6
MO+]$TO4[;1&\5:5(WG:?<[9%4=%P#N]QR01Z'ZUZI\/;>>#X;R130R1R9G^1
MU(/.<<55^$=C+%X:U"&[MG0/<D%)4(W#8.Q[4@.<^('B.V\3^#-&OH"%D\]E
MFBSS&^WD?3T]J*R?''@B\T'5V&GV\\VG7+&2(1J6V'NIQZ9X/I13 [.^\"76
MF@O: 748[C[X_#_"L:&YN].N-\$LD$JGD X_,5[/6;J6C6&IH1=6ZLW0..&'
MXUYE; +XZ;L>Q1S63]VLN9'GEQXTUF2W\D3(AQ@R(F&-8"07FIW16-);F=CS
MU8GZUU6F^'K*Y\0W%G*96AAY W8)^O%>@6=A:V$(BM8$B3T4=?KZUC0HU*^L
MY:(ZZV,I832E#5G%^%_!5U8ZA#J-^ZJT>2D*G)SC')KOATHHKU:5*--6B>'B
M,34Q$^>H%%%%:& F!2T44 )BEHHH *3 I:* #&**** $Q2T44 %%%% "8I:*
-* #%%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jul. 29, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001374690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 29,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Larimar Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-3857670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Three Bala Plaza East<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 506<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Bala Cynwyd<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(844)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">511-9056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LRMR<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d35960d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com//20250729/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d35960d8k.htm">d35960d8k.htm</File>
    <File>lrmr-20250729.xsd</File>
    <File>lrmr-20250729_lab.xml</File>
    <File>lrmr-20250729_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d35960d8k.htm": {
   "nsprefix": "lrmr",
   "nsuri": "http://www.larimartx.com/20250729",
   "dts": {
    "inline": {
     "local": [
      "d35960d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "lrmr-20250729.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "lrmr-20250729_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lrmr-20250729_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://www.larimartx.com//20250729/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2025-07-29_to_2025-07-29",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d35960d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2025-07-29_to_2025-07-29",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d35960d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.larimartx.com//20250729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.larimartx.com//20250729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.larimartx.com//20250729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.larimartx.com//20250729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.larimartx.com//20250729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.larimartx.com//20250729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.larimartx.com//20250729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.larimartx.com//20250729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.larimartx.com//20250729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.larimartx.com//20250729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.larimartx.com//20250729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.larimartx.com//20250729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.larimartx.com//20250729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.larimartx.com//20250729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.larimartx.com//20250729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.larimartx.com//20250729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.larimartx.com//20250729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.larimartx.com//20250729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.larimartx.com//20250729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.larimartx.com//20250729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.larimartx.com//20250729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.larimartx.com//20250729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.larimartx.com//20250729/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-25-169818-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-169818-xbrl.zip
M4$L#!!0    ( +LP_UJI%O?H,!,  #=Y   -    9#,U.38P9#AK+FAT;>T]
M:W/BQK+?_2NFV#SL4SPD ;;!7DYY6>\>W_A5QJFD[I?4( TP62$I,Y(-Y]>?
M[AE)B(< 8["]B5-)C)A73[^[IT><_GLT=,D#$Y+[WL>?S;+Q,V&>[3O<ZW_\
M^:S3OKCX^=^MO=-!"-V@JR>;#N,?"X,P#)J5RJ@KW+)D=KGO/U2@H6(95JT0
M=XQD*1P'3*:]>U1VR[[H5Y*6J>Z>[WG1,.W\^/A85M/C "<4%1Q1@4XEZ,4$
MMY-Q(Y=[WZ:&/5;5(+/1:%14:])UKF>Z@&48U0HV=ZED:7<Q%%/=72KXD(IP
M5+;](0)?-XZL1@J(Y(O @*G-RN]7EQU[P(:TQ#T94L].%XE"D0M2HP*M24<N
M_9IE'BV!/^Z1#ACE]36AKP>[9;]_NKN<= \7]Y]TK82">K+GBR$-@5]PIGK)
ML$K686:2$O##U$0)?ZR:Y[A4-5-<PN)\V59GL(BMS@Q?QIT/*[HQ[IK/*<CC
M!>1U1AWX$_+09:WCTB^G%?UQ[W3(0DIP>(G]%?&'CX6V[X7,"TOWP)L%8NNG
MCX60C<**FJX"HRIZ0D+(:==WQJU3AS\0&8Y=]K'@<!FX=(S,SPHM<LI'3>S-
M1/R9.P[S]&?H<JTYGWATB&,9;YX-F>? ?^$7E_9C"$;A'>M!<R04=O] /BT9
M1R6K\4?H9YX*A#L?"WST4*H:9J'5HZYDIY6IE>96QA'_44#] <O_<>X!:L9M
M6%]0]\)SV.@7-BYDX,OI\#0X6P:(4/6H=M@PYN&KS*!)L!X3H,*8A&>4Z*94
M@@=K[5)AJ)5017TL2#X,W/2[@<!-HBHI)0JC/)).TDR%+7SDA-6+5.+=3NU0
M/4L_$OI1R4TS1J^BUAKH388Q1:STD3OX18\S010*V4*I;E_\,DV@V<$(]<+Y
M Z"@[Z2/(- B_$Q#UIK EHR<M$U@=7+Z)BWILNDZE2GLI-B<8*^2%;\*B"G\
MR0@KCBI1E_>]I@U[8:(PW?[(G7#0/"[7N7>2Z>NR7G@"9J//O1)^;A(:A7[R
MC>#]0?S5S'2H+4L#IMK!, ?I)*$?-#./73\,_:'ZINL+ #[YQ@Q&1/HN=\@'
M0_U3:/WTP3PT3A;L+;M8=?5BUM,7"Y*E,A,?PS1D?AND!R0J2?Y?UC2/T^<>
M'7)WW+SG0R;)-7LD=_Z0>B>J[5%#WO5=YV0!F7Z]OK@__TPZ]V?WYYW32I #
MCO%"X'3.V[_>7=Q?G'?(V?5G<OY[^S]GUU_/2?OFZNJBT[FXN7X6C-8V8/R-
MR@$X@:'O%<GG<KM,+*->:\S -5GT> WVG'!$\#3!RC+GX4;,63:@VS1_GFAQ
MM<P?Y[>_IKAF&?PML/F7F[LK<BH#ZJ4J:<!#5H)O; 9F\U'0H-#*=28^^W:$
MOD3&F]G ES"M@O::IBWU:07A:KTST(X8:"M"#VKI[OSZGMR=W][<W;^^$KJ-
MA(RH%Y+0)QUF(PMJE)E5X@MBUO>=@]>'TN^1^P%# "/!0P[CST?V@'I]1L[L
MD$"SV:C6\N%\*>JB6X30W+' %R'93YX9!;>(R9"P!^A)A&IFSD$S/^Y(5,6M
M\JW.M<OU9)VA(T#4&V'3@0F&,'S@T/$8(&)>5J=4"ZW_B]RQ)K[5*!*<9E[%
MO.N67>@6J[8-[LOE)1TCWK$^EY@7"*^AY1GFIU9H7>H\#4HE6#P6A=R617+A
MV>45+/,TY6%L RW[YR,*2@+1@;(H4C00*HD,F(U!E$.X1W@H":@5$$TQJ_3>
M63V?U9^!F[W3D'9=1FSFNNA#85*T8!34<T =)WF.5XKW:ONN2P/)FLF'Y4Q"
MI@'4V# -X\<$=_'*32.&MFDDT2+ )]3_G>D0M%K[$;,%V88')D *J!NC5V]X
MME,\VEIO= +J7._L-*>5&$21M :TSTI=P>@WS(5RAS7I@P_LL#:63$6F9? !
M=1=JH*QG/"N;*Q44J ]?@&54FJ@3@KEJ^Y$7BG';=YYE^C!ABAF.D 7"?\!E
MIVU?'2PW<^DCV,1<ISITUB%WRMLKNF^(OXT##XW@+]QET-:%I3;7_H>8C#)+
MU<.Z.9<L3+'U-T+:/1U=Q*DV6V'IV1@\*K0LHU0]KA\='JV#PAU(^/&& KZI
M)=]*\+VO= *&)7X(?@?Y$X(!Z7 5M#S)S3!W !QX%CRKOY0#\4(2\+I4:?O#
M(9?R+1 !%1S1\OG/P?]%^:[<*9/S8>#Z8R9>G0C3VI)<^^4)+90J@_^AT_>=
MNI J*-F&#UDWMN(%UHY?S0N,X=NB1&PGXEMAT<\<1S IXS^7$'*9S[#FQX76
M_4 P1CY1EY);E_Z7DG,JPUG#7LS/]>2!93T#K$:AU8G V2%UX_!9,;GY>A1J
MP\<;<>\_>ILCPC(*+469]MA['#N;4D6Y'C?B%N('KJHB=A:-6&:A=<L\3X[=
M!^IQNHAXV[9K^8+\O(@N1MZM#]MU_Y\'&P5R$\Q8A9;9,(S:LB#M#3G+*W"W
M'V,'DU*! *[B 74)&S$["OD#YJK AC)Y\*:BJ7V@(D$R'LPA?8%9?UH*?BN:
M99+E_.G#L64>G4@2,I<% ]]CQ%.N81$]=3="SX! R$^!(8$I\A4!JJ$SZ/=,
M[JT"]HYKM8/Y"IN-(]1+'^AYBUM[;E!JU0JMNFF6&D9]@;E8=+#X)-INQ]/]
M DH4XCZ=R15*I\(CU6($5.T1?2@$+(]*FKA@AN/#EO)[0G=7YZ*KQ+;0:@^8
M_8U S$YH #8/E!W&\5U_1+K,]1^1<-B(Y%TM#.KD6S$DZ7$799A+$.B0>0X0
M/O2!]L/(#:G'_$BZ8R)!!F1OK%:(!_A=0)B.3GR]=.90(()Y@*F\<=+6@PC!
M?\1Q:*\Y!KJRF<M-AYO&+UN-3^:"DDG ,A\9S41.:UG/PL)0Y,>3Y48&F7*)
M.OM-\!#HB F%R(OC1_EL5ZOK^VZ7 @U#X+BLRJLC'1I'M=K)O,9[FO'4^\KP
M YEF ?)LTS>W6(PK0$X6623(G.??1<!6-:L>LW0X?8*.!^?[YA%I?[DC5M4H
M0\>GQ.GO?+XYGW= F=M !:]_!8H0M*&[.R8__)Z9?((HF%IC:I[#5UH,LT9+
MII48C8DP3-60)**P<C:K9I3UC <9Q^A=:G8N-;>"H67 NFQ50X<&7]ST>ANX
MO6M+S]'W+#TK61DP6K(S*$U$9)5-64/BG)*UWSW8KLSI.=^E[C6E[D+*B(D7
MD;WC=]G;2/:JK%3;M[<K>_&<:\O>MB/(C-^J0S4F(-@+<HM745$D\1OL-C]<
M>_/'3>\52YNE:-?(HN3L8$X&GG7 M8L3UGN\+:GKBNT!L5TJY59.!3;&V9M#
MD* HB*==46EUQD/HMB^W4Q#P*BC:13+U.BZ'52S$8LOPZK4#OD= _@"BB9:?
MMC5OI= Q-[37AFIL6ETEI<_(R#<*+?2\ "6=T+>_%4E !7F@;L3(#P8PGDD"
MO#@Z6%BU^#)G17E8B.5/B][F**B"XWMY=W7WUK:7$#EQJ#:JIY_U@U$&YPZ#
MJR9*JG3H7^2KZX.;3*ZH^,;FB@M>U!F[\!ST3QGICHFM4OLPXS<07*;*\F;R
MZ5P2<##!Q\5%^Z0O_,=P@&YN@#EV*HG#>MS3!?@Z8VG4$]=M)EVI[_E4R3[2
M]>A$92V3SER5[@=8NH]G0VOZRE:WE":&YM=<=,EH]:0)=.@WS\V? ;/\K/M*
M3PE)U,E/H76^F 8_?3@V&Q!D+3_*3P9_56/;>NC.@K^JM23XVR'6@+E[2]@5
M3XX7\CZ?.T8: &<S%X(2X&S/5R%*))GJ!?B*#ZOP)1U<G4/I*_2('[66.\;%
M'SDLC5+B 7S0(M@#ES .Y(5Z-B9#J6UCB3QVQM=U.%0X4A]3.4OCH^H^3>.C
M+)>78V9(<9\3-IGK7);//33]6]V[GSI#W=M;R)DF&\YQ)GZ5<6"Z#&@/#HS[
M2,<2?4- VM[I(/5U('#T1?-#0_USDNPG&&6#0]ME5*#Q&ZCP:V_%0?5VWZRP
M-YLU^W1S]_G\KM2^N;P\N^V<-Y,/WT/6S#373)LMKY:Y"-D0RU ,\P3XW%RW
MDN?%TU?+7'.]^CG>P\%C=I]0DIQ:D<]HNKFJ5CKK"Z82667RE.S0X39T]HU'
MYN^N%DG^)46RCXH/*6.!&#_A_H@&"S\W>0CXL96/CJ9A^MZ&FMH\.2!*U)1S
M@YCS=#;N4>@S+9K@;)OP_)I=(:5*#GC*PEPRH*;WC=Q2$7I,2')YV098'?(U
MZO>9![IFF/&*BMA<1,=-L$ P"9-3Y "9V!/)@)V!.=*MXI3H3CC8+!CX>;O8
M+JRR>)-% -2E"AU  UR92S2+-E.;E%3G4F 5V@=T]>,[V^9Q\:AN%$'?ZQA+
M;A/J+UP 3M6T.90!"&P=_<E5T=^6N3F-.//0&=.YG;CP(:B$(.K">*Q91%["
M4AEN*S3^4"U;QFY@O8D76PQGF63?;8"K HL,4RY=+";%J9WUT9/3;$NR?(:\
MX@?H3A6Q7E/87"K#A]Y;U2 .6/!,U1".=F*F6KJRCPX;^&+@)D8!T?H"C1LN
M!/)D%8]-JUB?\"/,ER775E$;Q(LNX5$E/:'?UU&?TB2JBFO"VAJ;VX%HJ;
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M%)]A2]@M'GCKS'"7#:C;2Y+<RCN+.R#+1E@!IJ8#V@Q\ 1MSYM*OS]!9I[H
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MOU7](4WT7\G1X>'1#ZB%/[-D@7G";[)RDKR VS;+YWGY\X;I]@GY9?YQ>:^
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MK><[(@DE%Q$@7%*%-F8V1;-1]7R&OVG  4>#=I3!VG/6VX<26.?Q.3RO*A"
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M,W/8'NN)PWE26&G).*[P&:TI_]AYR!N.)\MZB7)NK5LXD/O=@>BJO\Q&2->
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M0-KTE*N_R;=1L WJ_ZHLL)M)>8X-XOWO)UHE"&*_D8;4P1>E'S)RW=64^FS
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M/NPM>(B<)0HH31C;\\/# -MCV-)P L9IWR>[OUM6(&=@GC-BC(\"/\4PSKP
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M$FB=A(TRI7O_^\2^+S2W_"99*-B3+7+=#6VN9S0BES09$=L:*C^_UOXDX?;
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M,7HW'3]M"XF_EB8.6$4<-+*R.";C!2DXJ<-ET;7TZ:#2FSU[C^M91W_D1=1
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MG@0)O*#5ZCMP#8M)D=4%Q^B[0[])++Y3E6('C<,0 !!#2R:KL7AFL-T:-):
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M#,%0?30F@M!GYFQ4R17M[CA<A!4QPP<@T#,PTI*CA\1I@"KY["QF[7F_/R+
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M)":(Y3@-$5LK>E0/)F%QZ5XL#]%;GV8#]1#5)!<7:[*H,FAHZ:JA/HGB!48
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MZ=RH[]?EN9'PYV:]1@_5D3T\*\ILF)>3LR+S#VNR_6+[\4\/<4[JR/[53*B
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M&14 X/D! ?@X_+Z\LON#)=3V%O$DF8/WVYM_F ]_/?[P_M7_!U!+ P04
M" "[,/]:'@D67'P)  !&(   #P   &0S-3DV,&1E>#4Q+FAT;=5:ZW/:.A;_
MS@S_@X;[F':6AWGE08AG$J )]]+  &WW[C=A"Z-;6_9:=BC]Z_<<R<;&(6VS
M+=W9S#3%0CJ/WWG+Z=\OWT[,_OWH9FB62_WE>#D9F:-_UKKU9K^AGV"YD7Q/
M^K?3X5_D]FXPG4SGUY4/]^/EJ$(6R[\FH^N*RP6K;1AW-E'OP0\]ZE9,4B[!
M^0$3$0O-_G#\/MV\Y7:TZ5W4NUQ4"'6Y(X  6T<5Q6:6;O-HZ'!1B_R@9P31
M%4F>5WX4^9Y>6OLBJDG^F?6:V?.:>MS=]9;<8Y(\L"V9^QX%3C>3\=W#=25$
M(2MF_]8<?=KP%8\(*$SZC5NSWYB9.?XYXBT@7A#GB305\W>QDL&5HH)XWMQ.
M1F0PFDP6LYO!^.'NNF)4U//L9CA,GS^,A\O[ZTK3,'ZKD-OI?#B:J_5$!KU2
M \PG-[/%J)=^^**J15SVJEO*%@@S (TBSLWDPS 5Y/S\-\"FL1QFW[Q/3FM5
M,Y'3C8<$6JUT'7[-<ZQ2E0+JL-HJ9/1CC0O);=:CCSZWR<M4,@O"@5FT7K \
M?GM'%O/!=<5I=R_/#,<X;QO-9KO3ZEX:9_6_ P<!65Y7)M.[:47Y>*9%0=G$
MIJEEG^Y3?$_GM.:=[]M;+L@L]"VP'>DOWMY,)B8X4;^A/Q:\]D<+T#9:7?*'
MOQ'D3;GT)Q."V3MRZS[:9+;A+K69&VPXK9+9#6E>-HW.EX.(?%6\@S ZG5J.
MKX%UZ;9N^1YR \-^([OFB]G]HTDZG2YI&>?D_,(PD%T^1N _S!;/*'R W/>F
MOS0'_!&[.XUTZ[(*@H&5OP#"#Q'!G-"0 PVRW+"0!BR.N"6K9"RL.GG>W#^&
M]7(3,D9NJ4O)S*6?*1E1&57)(N81(UWC#&UP4H=3K <[L=W92; 81J>H]@\I
M.3^V=.1J4K%V%6M;OI:92=*7T<YEY)H\E_8KA?+1@3*8SZVIV^K^8,YZ^22<
M_^[9C%Q(.>1[37E%"D+UWYD+9L4ACSCLFS.'2X@P9I-8V)"Q]4)((^X+LHAH
MQ#P(00(/;Z!1(OTWTX?EOC/:@#O69$ MUA/^%H*D8BYJ[7X#-T&R>&=J/\UR
MQT_('.8'1C;TD1$*%<@F5!++CX5D+HE\LO-C N7)\J$P6$K%+8\VN!R2-8>V
MT"'^FM"OH !:?3L,Y-4;#C[UU1,/?EV'1[O=KK7.+UOGW==[$J %!0EL4,@/
MB8R#P%42,8C.:,/([[\T.^=7QZ7&[RZN7J-^>%R0MS1)I3J3=C0&2";G&%38
M9/3)VE#A,#+P/8]+"63+I5<9OVPYY1'$H8PI( 58%PC>6!%BV[QLMZLDIT^.
MWN'NA&:5A,P%E< T"=$PKR:0Q#5_O0;G7>W(\TD;N)(AD-K2D($'A(&?D#C4
M**!BMV<-U., ^)9+O[8-HVKH?\I'Q Z(>"LN]G+(3/Q$JF@7P(,,F,77''2%
MM9!Q44?IGO.Q+6!C,\NE&),,U (_!6\&U9!B!OF!)5L=;<HZ4 4@F+ 8X1)"
MR6:(&KJW'W"!QUP686=F4XR.)ZZ 9N?"<F-;Q4ZYE)\Z$OR/"W[ZH@B!C::#
M'@X "95#;$#)+!JH6]3R2*RC!D'HHU&B.']:^4&YI!UAENU8['<\B:2L*VD;
M25>2V0D=*6.9,UP^2.8QY(8. *^S[].8T;YR5!P=&+ ML8N* 82E($/JQ*35
MK';/6M4N>+#< )3R0.6%6DIUA$/@WAZ(*R/?^E@EOQIUPVB2 &+KD;HQ@ CR
M*C*% /*45\"9?!3EY;'\1U5P$C&?<R?46\N4>B1X)QA8[7-"BMDO55VAMP74
M6*C@ (@A=4F6* [GJ&US/ D^TJI>-!4*Y9*F?\ +%5HQA%'Z[IZ!9" SG#U@
M)""'8;A45=CDS(H+V5:D11UHZ)31*.#C'."!AV5L;0Z)YT!]EZ=TDU)*X*V?
MOA%.*VK('CG;LD1:V[=BE$/7"I5JU#K[!&2RK @)%]/]-J%AH_"06@*(P2#D
M8&V$V,$4IWPXB5_)(I IA.!9,=??UDDF@\NQZF%@^7%4+G$ )\!2 MAB6EAS
M2_&N8H!:+(STBD[*0;QRN861PBU.726ZJD8@@T<C!3QL6T/O@,] CKK[\#HN
MVE$^BD%"+&?JGV"KY?.28D5PN<=S<;.OAW=,*/\>Y.KB!(;-TPM\"V&JDBG*
M ](RQP<WKZ+#H&!I?4]4BC8TTEE21ZORB15C@MB0BPF-P2M"X&QKRVXW^(TN
M&'H-$ABWD0_6!FI!'V!3K);[1 U&]U*[E4O'0P_=SW6!+Z9";@-C2.TQNN4Z
M=N%)\4!F7^WZA"]J5$HF)5VYK)XV?*<NI=-<0Y!Y"5U!9@95RB49K_Z&<H-N
MLJ+B8Q@'D;6K F20$Q^ANX#/ZY#&@#F&'21O(:'V8*OFAPX5_',2@A[Z$A@D
M]A0</C9 1((/0GN#F4$![22^!SG!38*74-WX))E278+J/!-B^DA:+ MLRH&\
M_@;32$()$HNP.)1)M8W]&\;F+/8:P_%[&$22FUYUWX<#6J"'OT.PF?<$:US*
M38<KAC[;H^Z6[B1.<HT F=S/R6+\+S!=NY+253?1O5\NU4_A*C69T :CA^5H
M_E_>19_R-OIK=R'??AGU<M;/7/V<4-D9F)>T4L6"9]@\X4+R;"X.[SM.:IPE
MML&%SE=%1"YQ0@L/G7!$(82Q:]/9BZ.#!2&+5!MS-!U"06!DJHF42[,LL*!H
MJFHJ-_KP>8?TQ^9M++F ;(;%8\?"?F-LDHMFE[Q:Q)X'8K6,YN7KGW%_ED,$
M/NJ&;AV'0LN;7 6LU3"]2AOSI"CF6G6<4T%ME@Q!V89T2CR[DF00AR&FP3F#
MTOF"JY*+VI_[ 3_701]02]OQX@RLRQ\6. XM%U<M<E*Z=6<=9G.@^&*;C8T5
M[%QA7RXDV\_NV%E!URWW0W8.48 EF0NUA^>&PP(826+68WLBD4Q'TC4'F++!
MQZ*ZM]<X3)@#F?RM;LHT#*DJ1Z>A.F0C["/5'0X03[11C83M$^&#,+:'1L06
M(NDN$H+8MSE^B*-2N01SC82S *TOV1X4T#[$0I+=E"WT5*D1.$\;E>*-AU8M
MC%V6UB\G=I41I+X.4,2>1,1W7*VJ>G'X]O#%+_@ZIWR_]Z47>OHV]G_T0NX]
M Q>(0FPD\4905C,Y#F7($<O1NA^-[^Z7H,-97H.?)GU#-DCQ_9MZ\?9_I,/=
M=#K\,'X@L_ET )W0T?>'3]]#Z9:.'._M^@W\2P!85'\_\!]02P,$%     @
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MMVXXGK.$)MN)*B/\Z%)=@#>_DZTMEA7)'>%9;X77!+G@6B.(A&U6 ?(2D-8
M5<09X!9;+X/<O'\WI,]XL-)S,U7=VY*\F],1P,;&^?XQ%USW=9 H+81!*SNC
MB=]FF4C+7G$PO"&"\O"<A6?JQYFF/#Y*[AA,LQ5>$X2!JD$0F]FL!*@:H(N@
MX=M"ZT:.K?O'6"Q\(G.J%\DL^>C'UD2;<SM=*E08X=4Q[@L%DQ[N.N&A N@2
M2*N$-OHV+!*LF\< ^9(%7"RY2&^5W"9J<"9\I18IVPD/&W)]0*I3S.UL<NL4
M]R&PD,>=B9V"D%:$O"3HFDA#\@U\&6;FZ>8PANB"1N3C*IX1T6QBRGF=CH?!
M #<?=P?_L18NY5H=,GDDH+'[-=!KU30&J%-_<QFJQ1*]H]G-\:=06RG2*<*'
MK'&+8'>X:X5Q25>E8+<6+O>M6C$,P1/\8(S$:1@J S+_YXHR,FPV#D:!3D>A
MSA(_$.@^ I6BN/CG^B^+#="5X)IAK6-:LV% _PE>VD%_Y(K^Z-FA/[)%?]0&
M^J-OA_YTS5M#'\F&-?JU7A#1GZC-:S'E:_8D\,OISP%[@QT3] ]A:,@_EFP)
M>%T&N !="!=V; -UJ-NY0,0\_7GX6MP(?D]9T/"V3I7&<P"^RIB)^D>Q:.@;
M=5OB/[NQH= IJN$.02M6ZB:A@1_$<;CA,O&CO^FR^3U.L\)S& 6S*=,@[$2B
MC8%!M:4AR"J!*H5YW[(]&W4#8.W%\1U ;5 0OPGPNSE=O0%H:ISO'W-Z_V]/
M!PG<]/]YK8S#*7Z?.^_^63;K!J)^*3>Z67#6\'[Y?EY'0%8:X.;C+F":M9#@
M3,4A5<>Z;]A.OV5(FS3M!NJ?@B8)81,>QRN6WX^4MK16)'>$;+T57A/D F^-
M(!+!>078+>%,<8N-EU%NVKT;SK<\H@%-*)M_4"MN0?W(EF539D<@UYC@51$N
M"%>I(?'[( ^%OC.\;;5<)K=1WV[8W@BBYX,H+-(W(?6G8\3UW9W]PJ%.H2.,
M+4SQ0Y$N6!]21<);E8%R'<@*05K)&?2V392!?Z(35/0OI5P1X3X !IWG,0;5
M!LW#L!>/.!(5VFT-1E:NU?EHR5'ME#2RY;B\(<%*K:>VP]%L2I/(^A['?EY7
M2YLJ ]Q\W&E98]3"6M3DXJ#4(95W7].TTN_.BJ9!TVZ@3H6O/VI^NXUGW'H)
M_BBI(T3-K7/#01<X#4)(9.;*D$D[4]E"HV4D;;O%N6Z>;X*%<DN:?)C!G-OQ
M]=-HA%?'8%Q']_6PKZ5%!9P/,[37M_&::MD\QO.]\YB(N9J:WP1?)PNU&%GZ
MK.$'>2LD.GW"5V^+'PQU?\97(XO$>OY@K"@$627(2R$]XVO1AN$AGZV7\HXK
MM:5_Y4J^BV:_>$3M^1]02P,$%     @ NS#_6DI"@S["!   02P  !4   !L
M<FUR+3(P,C4P-S(Y7W!R92YX;6S5FEV/XC84AN]7VO_@IC>MU) )S'06-.R*
M,C,KU/D2L&W5FY5)#F#5L9%M!OCW/0ZX)1!F879;Q5SPX?@]?GT>Q\1.KCXL
M,TZ>06DF13N(:V<! 9'(E(E).YCKD.J$L8!H0T5*N130#E:@@P_OW[ZY^BX,
MR?5M[X&$9&K,3+>B:+%8U-(Q$UKRN<&0NI;(+")AZ.IWAY_(;^OF6J0/'*@&
MDE%M0)%?YHRGK?I9_3R.Z_5:O"U30&T\DE(#+7(9->((*UZ09BM^U[JHD\X]
MN<FC"#)D&6Q+Y6REV&1JR _)CR0774LA@'-8D5LFJ$@8Y63@'/]$>B*ID0[G
MI&]E&FUJ4,^0UC91.1-_M>S;R)HG;]\0?&$>A<Y+VX'-QB89RY'B-:DFZ/:L
M$3E1L*U9[HD6C5P2-YO-*#]:K*]966UL(([^N+\;)%/(:(@,D%FRTQ2Z2<T_
MZFUS%]'ZH*NO64OGD>YDDJ?^B&Z1@S7LK]!5"VU1&-?#1EQ;ZC1X;YM<9U5)
M#GT8$_OYJ=\KM,FI8AE59IF/J1S_V66]&1FZE$)FJ\B*HFN9S#,0QGUV1'HC
M##.KGAA+E>5="4B>U=94P;@=<)6IT$6SAK[O8Z#/IP0RJQF>&)IE,PX!B;8Z
M-%,X>(3):]]A04$ 2P,BA=2%L1WXK[K\?LUU,WAE4DB!.WUS:!J2VD0^1RDP
MV^*Y_6+S<Y[G!G]\[DJ<,3HC;11-3#$'W(X6J5PAIR/@[:!$%'U+0QWL=FJ[
M?LOIY%A#.Z*BH6UN'9440E*5N'#X=0]:<>1O:D0SJC!>F$QQCG/JL9)9:7(V
MK<E2HU*EH-H!SI!XQ@=DIIA4"!M+ C+7Z$7.K&O*[3$8@U*0WJV[?=!E;A%G
M3PUYS6^,9ST:N]@#17D/1_SR5U@=B^F N+JX#AAVV!K>8'/SR1#3>"RMHJ:Z
MD(H^'9L+[]@\ 7K%Z3Z]Q@NC4R'MB*M/:\>PP_:S-]C6<T,?)LQV5)@'FAU-
MK5Q;76CE?AVS2\^8X:) JIE4>6H'F&'HRCE.\:NN3$]$^(5052?Z!?L.\#O/
M -\R#@_S; 3J-)K;NJJCV_;J.#4]XS2DRUZ*:6!CMEZ8O@;:P2!5)WC0^ 9G
MX\PSG)TTQ23KS0<ND2$^#65I@*IC+#7M$,;>(ZQ_+<*ZCPCK_R+T;6V^Z447
MOSZJH5R(5P'<EGN";]NR@^?/"KW0E?Q2[%$]*?G,[,;O:PCNQ? $XYYOQ_+<
M3Y9/4AO*_V2STU<7Y1$\X;CCVE'T9U_&SB<=!?04;D5-=4D5?3HV_FR^V#M9
M_&DJQ8GKO'U==1GM>W6<_-EP^1W]&1!=F65SL5GFZ&-A'1!7E]@!PPZ;/]LH
M \E9P@P3DWO\,U;,6CN.69FRNL#*W#I:_FRF/"FP0P[P:BF_#V)O1*O'\?CX
M:?&E"-6E]Y+K#<5S?_90=GK3TWH.ZNM9EL3QAFB)=\?5GXV5 21S:S&NCX;,
M\*,O)?=UU>6V[]5Q\F?W9*BH?51NL,I&\NB_NQU1=0GM&'5X_-D?<4/L9IE,
MJ9C *;=;R[75A57NUS'S;1_D)@,UP;'W4<F%F>+\/J/BQ$>&#H2H+L$7;3N0
M_\-6R%6TEYH[++"/OJZ/V#?[(">6_ U02P$"% ,4    " "[,/]:J1;WZ# 3
M   W>0  #0              @ $     9#,U.38P9#AK+FAT;5!+ 0(4 Q0
M   ( +LP_UHS2J!Y/+8  -FJ P /              "  5L3  !D,S4Y-C!D
M97@Q,2YH=&U02P$"% ,4    " "[,/]:'@D67'P)  !&(   #P
M    @ '$R0  9#,U.38P9&5X-3$N:'1M4$L! A0#%     @ NS#_6J$-&;Y
M P  3PL  !$              ( !;=,  &QR;7(M,C R-3 W,CDN>'-D4$L!
M A0#%     @ NS#_6K4DA:1[!@  N48  !4              ( !W-8  &QR
M;7(M,C R-3 W,CE?;&%B+GAM;%!+ 0(4 Q0    ( +LP_UI*0H,^P@0  $$L
M   5              "  8K=  !L<FUR+3(P,C4P-S(Y7W!R92YX;6Q02P4&
2      8 !@!Z 0  ?^(

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>d35960d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lrmr-20250729.xsd" xlink:type="simple"/>
    <context id="duration_2025-07-29_to_2025-07-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
        </entity>
        <period>
            <startDate>2025-07-29</startDate>
            <endDate>2025-07-29</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2025-07-29_to_2025-07-29" id="ixv-301">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2025-07-29_to_2025-07-29"
      id="Hidden_dei_EntityCentralIndexKey">0001374690</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2025-07-29_to_2025-07-29" id="ixv-312">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2025-07-29_to_2025-07-29" id="ixv-313">2025-07-29</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2025-07-29_to_2025-07-29" id="ixv-314">Larimar Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2025-07-29_to_2025-07-29" id="ixv-315">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2025-07-29_to_2025-07-29" id="ixv-316">001-36510</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2025-07-29_to_2025-07-29" id="ixv-317">20-3857670</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2025-07-29_to_2025-07-29" id="ixv-318">Three Bala Plaza East</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2025-07-29_to_2025-07-29" id="ixv-319">Suite 506</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2025-07-29_to_2025-07-29" id="ixv-320">Bala Cynwyd</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2025-07-29_to_2025-07-29" id="ixv-321">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2025-07-29_to_2025-07-29" id="ixv-322">19004</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2025-07-29_to_2025-07-29" id="ixv-323">(844)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2025-07-29_to_2025-07-29" id="ixv-324">511-9056</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2025-07-29_to_2025-07-29" id="ixv-325">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2025-07-29_to_2025-07-29" id="ixv-326">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2025-07-29_to_2025-07-29" id="ixv-327">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2025-07-29_to_2025-07-29" id="ixv-328">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2025-07-29_to_2025-07-29" id="ixv-329">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2025-07-29_to_2025-07-29" id="ixv-330">LRMR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2025-07-29_to_2025-07-29" id="ixv-331">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2025-07-29_to_2025-07-29" id="ixv-332">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
